

PROSPECTUS SUPPLEMENT
(To the Prospectus Dated July 30, 2019)

TITAN MEDICAL INC.

6,500,000 Common Shares
11,500,000 Pre-Funded Warrants
9,000,000 Common Warrants

This prospectus supplement (a “**Prospectus Supplement**”) of Titan Medical Inc. (the “**Company**,” “**Titan**,” “**we**,” “**us**” or “**our**”) qualifies the offer and issue (the “**Offering**”) of 6,500,000 common shares of the Company (the “**Common Shares**” or “**Shares**”), common share purchase warrants to purchase up to 9,000,000 Common Shares (the “**Common Warrants**”), up to 9,000,000 Common Shares issuable upon exercise of the Common Warrants (the “**Common Warrant Shares**”), 11,500,000 Pre-Funded Warrants (as defined below) and up to 11,500,000 Pre-Funded Warrant Shares (as defined below). The Common Shares, Pre-Funded Warrants and Common Warrants will be sold in fixed combinations at an offering price of \$1.00, consisting of one Common Share and one-half Common Warrant or one Pre-Funded Warrant and one-half Common Warrant, with each Common Warrant exercisable to purchase one Common Share at an exercise price of \$1.00 per Share for a period of 4 years following the date of closing of the Offering (the “**Closing Date**”).

The Pre-Funded Warrants will be issued to those purchasers whose purchase of Common Shares in the Offering would result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% of the outstanding Common Shares following the consummation of Offering. Each Pre-Funded Warrant will be exercisable for one Common Share (the “**Pre-Funded Warrant Shares**”) at an exercise price of \$0.0001 per Share (the “**Pre-Funded Warrants**”). Each Pre-Funded Warrant will be exercisable upon issuance and will expire when exercised in full. The Common Warrants and the Pre-Funded Warrants are, together, the “**Warrants**”. The Common Warrant Shares and the Pre-Funded Warrant Shares are, together, the “**Warrant Shares**”. The Common Shares, Warrants and the Warrant Shares are, collectively, the “**Securities**”.

Pursuant to this Prospectus Supplement, we will also issue warrants (the “**Placement Agent Warrants**”) to purchase up to 1,260,000 Common Shares, and the Common Shares issuable upon the exercise of the Placement Agent Warrants (the “**Placement Agent Shares**”), to H.C. Wainwright & Co., LLC (or its designees) as part of the compensation payable to it for acting as our exclusive placement agent in connection with this Offering. The Placement Agent Warrants will have the same terms as the Common Warrants except the exercise price will be \$1.25 per Share (which represents 125% of the offering price per Common Share and Common Warrant combination sold in the Offering) and they will not be transferable for 180 days from the date of effectiveness or the commencement of sales of this Offering.

Our Common Shares are listed on the Toronto Stock Exchange (the “**TSX**”) under the symbol “**TMD**” and the NASDAQ (the “**Nasdaq**”) under the symbol “**TMDI**”. On June 8, 2020, the closing price of the Shares on the TSX was CDN\$1.70. On June 8, 2020, the closing price of the Shares on the Nasdaq was \$1.27. The TSX has confirmed that the Company qualifies as an “Eligible Interlisted Issuer” pursuant to Section 602.1 of the TSX Company Manual. The TSX has also confirmed its understanding that Nasdaq will be regulating the proposed issuance of the Shares, the Warrant Shares issuable on exercise of the Warrants and the Placement Agent Shares (as defined herein) issuable on exercise of the Placement Agent Warrants (as defined herein), and as a result, the TSX will defer to Nasdaq and will not apply its standards with respect to certain otherwise applicable TSX rules. The TSX has determined to accept notice of the Offering and has conditionally approved for listing up to an additional 28,260,000 Common Shares. Titan has notified Nasdaq of the listing of the Shares, the Warrant Shares and the Placement Agent Shares. Listing will be subject to our fulfilling all of the listing requirements of Nasdaq and certain conditions to the approval for listing on the TSX which include delivery to the TSX of a copy of written approval from Nasdaq of the listing no later than the close of the business day following the closing of the Offering. There can be no assurance that the Shares, the Warrant Shares and the Placement Agent Shares offered under this Prospectus Supplement will be accepted for trading on the TSX or the Nasdaq. We do not intend to apply to list the Warrants on any national securities exchange or any securities exchange in another jurisdiction. **There will be no market through which the Warrants may be sold and purchasers may not be able to resell the Warrants purchased in the Offering. This may affect the pricing of the Warrants in the secondary market, the transparency and availability of trading prices, the liquidity of the Warrants, and the extent of issuer regulation.** See “Risk Factors”.

We have retained H.C. Wainwright & Co., LLC (the “**Placement Agent**” or “**Wainwright**”) to act as our exclusive placement agent. The Placement Agent has agreed to use its “reasonable best efforts” to arrange for the sale of the Securities. The Placement Agent has no obligation to buy any of the Securities from us or to arrange for the purchase or sale of any specific number or dollar amount of the Securities. There is no required minimum number of securities that must be sold as a condition to completion of this Offering. We have agreed to pay the Placement Agent fees set forth in the table below, which assumes that we sell all of the securities we are offering.

	<u>Per Common Share or Pre-Funded Warrant and Common Warrant</u>	<u>Total</u>
Offering Price	\$1.00	\$18,000,000
Placement Agent Fees⁽¹⁾	\$0.07	\$1,260,000
Proceeds, before expenses, to us⁽²⁾	\$0.93	16,740,000

- (1) We will pay the Placement Agent a cash fee equal to 7% of the aggregate gross proceeds. We have also agreed to reimburse the Placement Agent for certain of its expenses and issue to the Placement Agent the Placement Agent Warrants, as described under the “Plan of Distribution” on page S-34 of this Prospectus Supplement.
- (2) The amount of the offering proceeds to us presented in this table does not give effect to any exercise of the Common Warrants or Placement Agent Warrants.

We anticipate that delivery of the Securities and the Placement Agent Warrants will be made on or about June 10, 2020, subject to the satisfaction of certain closing conditions.

H.C. Wainwright & Co.

Investing in the Securities involves risks. You should review carefully the risks and uncertainties described under the heading “Risk Factors” on page S-15 and under similar headings in the other documents that are incorporated by reference into this Prospectus Supplement.

Neither the Securities and Exchange Commission (the “SEC”) nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this Prospectus Supplement is June 8, 2020.

TABLE OF CONTENTS**Page*****Prospectus Supplement***

ABOUT THIS PROSPECTUS SUPPLEMENT	S-5
WHERE YOU CAN FIND MORE INFORMATION	S-6
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION	S-6
DOCUMENTS INCORPORATED BY REFERENCE	S-9
RISK FACTORS	S-15
USE OF PROCEEDS	S-20
DESCRIPTION OF THE SECURITIES	S-20
COMMON SHARES	S-20
COMMON WARRANTS	S-21
PRE-FUNDED WARRANTS	S-22
PLACEMENT AGENT WARRANTS	S-23
CERTAIN UNITED STATES FEDERAL TAX CONSIDERATIONS	S-24
PLAN OF DISTRIBUTION	S-34
DILUTION	S-35
EXPENSES OF ISSUANCE AND DISTRIBUTION	S-36
LEGAL MATTERS	S-36
EXPERTS	S-36

Prospectus

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION	6
PUBLICALLY AVAILABLE INFORMATION ON TITAN	8
DOCUMENTS INCORPORATED BY REFERENCE	9
RISK FACTORS	10
MATERIAL CHANGES	10
CONSOLIDATED CAPITALIZATION	11
DESCRIPTION OF SHARE CAPITAL	11

MEMORANDUM AND ARTICLES OF ASSOCIATION	14
USE OF PROCEEDS	22
PLAN OF DISTRIBUTION	23
DESCRIPTION OF SECURITIES	24
TRADING	25
DILUTION	25
EXPENSES OF ISSUANCE AND DISTRIBUTION	26
DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES	26
MATERIAL CONTRACTS	26
EXCHANGE CONTROLS	26
CERTAIN INCOME TAX CONSIDERATIONS	27
DOCUMENTS ON DISPLAY	27
EXPERTS	27
LEGAL MATTERS	27
INTEREST OF EXPERTS AND COUNSEL	27

ABOUT THIS PROSPECTUS SUPPLEMENT

This document is in two parts. The first part is this Prospectus Supplement, which describes the terms of the Securities being offered and also adds to and updates information contained in the second part and the documents incorporated by reference therein. The second part, the Form F-3 registration statement (File No. 333-232898) that was declared effective by the SEC on August 2, 2019, of which this Prospectus Supplement forms a part (the “**Registration Statement**”) gives more general information, some of which may not apply to all the Securities being offered under this Prospectus Supplement. This Prospectus Supplement is deemed to be incorporated by reference into the Registration Statement solely for the purpose of the Offering constituted by this Prospectus Supplement. Other documents are also incorporated, or are deemed to be incorporated by reference, into the Registration Statement and reference should be made to the Registration Statement for full particulars thereof.

Investors should rely only on the information contained in or incorporated by reference in this Prospectus Supplement and the Registration Statement. We have not authorized anyone to provide investors with different information. We are also not making an offer for the securities covered by the Registration Statement in any jurisdiction where such offer is not permitted. An investor should assume that the information appearing in this Prospectus Supplement or the Registration Statement is accurate only as of the date on the front of those documents and that information contained in any document incorporated by reference herein or therein is accurate only as of the date of that document unless specified otherwise. Our business, financial condition, results of operations and prospects may have changed since those dates.

You should not consider any information in this Prospectus Supplement or the accompanying Registration Statement to be investment, legal or tax advice. You should consult your own counsel, accountants and other advisers for legal, tax, business, financial and related advice regarding the purchase of the Securities offered by this Prospectus Supplement. If the description of the Offering varies between this Prospectus Supplement and the accompanying Registration Statement, you should rely on the information contained in this Prospectus Supplement.

We have prepared this Prospectus Supplement in accordance with United States disclosure requirements. All our financial statements that are incorporated by reference into this Prospectus Supplement and the Registration Statement have been prepared in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board (“IFRS”) and thus may not be comparable to financial statements of United States companies.

WHERE YOU CAN FIND MORE INFORMATION

We have filed with the SEC the Registration Statement under the Securities Act of 1933, as amended (the “U.S. Securities Act”) with respect to the Securities offered by this Prospectus Supplement.

We are subject to the information requirements of the U.S. Securities Exchange Act of 1934, as amended (the “U.S. Exchange Act”), relating to foreign private issuers and applicable Canadian securities legislation and, in accordance therewith, file reports and other information with the SEC and securities regulatory authorities in Canada. As a foreign private issuer, we are exempt from the rules under the U.S. Exchange Act prescribing the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the U.S. Exchange Act.

You may read any document that we have filed with the SEC at the SEC’s public reference room in Washington, D.C. Investors may also obtain copies of those documents from the public reference room of the SEC at 100 F Street, N.E., Washington, D.C. 20549 by paying a fee. Investors should call the SEC at 1-800-SEC-0330 or access its website at www.sec.gov for further information about the public reference rooms. Investors may also read and download documents we have filed with the SEC’s Electronic Data Gathering and Retrieval system at www.sec.gov.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

Forward-looking Statements

This Prospectus Supplement, the Registration Statement and the documents incorporated by reference herein and therein, contain “forward looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward looking information” within the meaning of applicable Canadian securities legislation (collectively, “**Forward Looking Statements**”). All statements, other than statements of historical fact, that address activities, events or developments that Titan believes, expects or anticipates will, may, could or might occur in the future are Forward Looking Statements. The words “expect”, “anticipate”, “estimate”, “may”, “could”, “might”, “will”, “would”, “should”, “intend”, “believe”, “target”, “budget”, “plan”, “strategy”, “goals”, “objectives”, “projection” or the negative of any of these words and similar expressions are intended to identify Forward Looking Statements, although these words may not be present in all Forward Looking Statements. Forward Looking Statements included or incorporated by reference in this Prospectus Supplement, the Registration Statement and the documents incorporated by reference herein and therein include, without limitation, statements concerning:

- our commitment to developing the robotic surgical system with the objective of substantially improving upon minimally invasive surgery (“MIS”);
- our intent to initially pursue gynecologic surgical indications for use of the single-port robotic surgical system;
- the development of the single-port robotic surgical system patient cart to deliver multi-articulating instruments and 3D high definition vision system into the patient’s abdominal body cavity through a single access port;
- our technology and research and development objectives, including achieving development milestones, estimated costs, schedules for completion and probability of success;
- our intention with respect to updating any forward-looking statement after the date on which such statement is made or to reflect the occurrence of unanticipated events;
- our expectation that the U.S. Food and Drug Administration (“FDA”) will grant Investigational Device Exemption (“IDE”) approval and that Titan will then proceed to collect suitable confirmatory human data to support its 510(k) application to the FDA, and Technical File for the CE mark;
- our expectation that Titan can in a timely manner produce the appropriate preclinical and clinical data required for its 510(k) application to the FDA, and Technical File for the CE mark;
- our expectation with respect to launching a commercially viable product in certain jurisdictions;
- our intentions to develop a robust training curriculum and post-training assessment tools that will be effective in ensuring that surgeons are appropriately trained to safely operate our single-port robotic surgical system;
- our plans to develop and commercialize our single-port robotic surgical system and the estimated incremental costs (including the status, cost and timing of achieving the development milestones disclosed herein);
- our plans to design, create and refine software for production system functionality of our single-port robotic surgical system and the estimated incremental costs (including the status, cost and timing of achieving the development milestones disclosed herein);
- our intentions with respect to initiating marketing activities following receipt of the applicable regulatory approvals;
- our expectations for the surgical indications for use, and the anticipated benefits of, our single-port robotic surgical system;
- our intention to continue to assess specialized skill and knowledge requirements and the recruitment of qualified personnel and partners;
- our belief that the specialized components, parts and know-how necessary for the manufacture of our single-port robotic surgical system, suitable for clinical use, will be available in the marketplace;
- our belief that existing and planned systems will be suitable to support activities related to filing applications for regulatory clearance;
- our continuing efforts to secure our intellectual property and expand our patent portfolio by filing patent applications as we progress in the development of our robotic surgical technologies and potentially by licensing suitable technologies;
- our intent of seeking of licensing opportunities to expand our intellectual property portfolio;
- our intended use of proceeds of any offering of our securities;

- our expectation that the proceeds from the Offering will be sufficient to fund the work described in this Prospectus Supplement;
- our intention with respect to not paying any cash dividends on Shares in the foreseeable future;
- our intention to retain future earnings, if any, to finance expansion and growth;
- projected competitive conditions with respect to our products;
- the estimated size of the market for robotic surgical systems for abdominal surgery and in particular our single-port robotic surgical system;
- our plan to focus on the development of our single-port robotic surgical system at estimated incremental costs and according to its projected timeline;
- the potential market for the Securities issuable under the Offering;
- subject to securing sufficient funding, our plan to pay our Primary Supplier (as defined herein) in full satisfaction of the outstanding payables by the end of the current calendar year; and
- our intended use of the proceeds from the Corporation Loan Facility (as defined herein).

Such forward-looking statements reflect our current beliefs and views with respect to future events and are subject to certain known and unknown risks, uncertainties and assumptions. Many factors could cause actual results, performance, or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others:

- risks related to our ability to carry on our business as it is now conducted and as we propose to conduct it with the financial resources currently available to us;
- risks relating to our ability to obtain additional financing;
- risks relating to our history of losses;
- risks and uncertainties relating to the generating of sustainable earnings from our contemplated products;
- risks related to loss of key members of management and/or ability to attract and retain qualified employees;
- risks related to dependence on third party contract development and manufacturing service providers;
- risks related to dependence on third parties retained to conduct preclinical studies;
- risks related to increased competition in the robotic surgical market;
- risks related to licensing and/or infringement of intellectual property rights of third parties;
- risks related to our ability to resolve the outstanding Civil Claim (as defined below);
- risks related to the price and volume volatility of the Shares;
- risks related to governmental regulations and approval processes of Food and Drug Administration of the United States Department of Health and Human Services, including possible changes thereto;
- risks related to acceptance of our technology;

- risks related to the ability to maintain the listing of the Shares on the TSX and Nasdaq;
- risks related to unforeseen global instability from an outbreak or pandemic of contagious disease, such as the novel coronavirus (COVID-19) (the “**coronavirus**”);
- risks related to our working capital deficiency;
- risks related to a senior secured loan from a global medical technology company; and
- risks related to the Medtronic Agreements.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein. This list is not exhaustive of the factors that may affect any of our forward-looking statements. Forward-looking statements are statements about the future and are inherently uncertain, and our actual achievements or other future events or conditions may differ materially from those reflected in the forward-looking statements due to a variety of risks, uncertainties and other factors, including without limitation, those referred to in this document under the heading “Risk Factors”, in our Annual Report on Form 20-F for the year ended December 31, 2019, and elsewhere. The forward-looking statements in this Prospectus Supplement are based on the reasonable beliefs, expectations and opinions of management on the date the forward-looking statements are made, and, except as required by law, we do not assume any obligation to update forward-looking statements if circumstances or our management’s beliefs, expectations or opinions should change.

For the reasons set forth above, investors should not attribute undue certainty to or place undue reliance on forward-looking statements.

Additional risks and uncertainties relating to us and our business can be found in the “Risk Factors” section of the Registration Statement, as well as in our other documents incorporated by reference herein.

DOCUMENTS INCORPORATED BY REFERENCE

This Prospectus Supplement is deemed to be incorporated by reference in the Registration Statement solely for the purpose of the Offering. Other documents are also incorporated or deemed to be incorporated by reference in the Registration Statement and reference should be made to the Registration Statement for full particulars thereof.

Copies of the documents incorporated by reference in this Prospectus Supplement and the Registration Statement and not delivered with this Prospectus Supplement may be obtained on request from Titan’s Chief Financial Officer, 155 University Avenue, Suite 750, Toronto, Ontario, M5H 3B7 and are also available electronically at www.sedar.com and www.sec.gov.

The following documents, filed by Titan with the securities commissions or similar regulatory authorities in certain provinces of Canada and filed with, or furnished to, the SEC, are specifically incorporated by reference into, and form an integral part of, this Prospectus Supplement and the Registration Statement:

- (a) Our Form 20-F Annual Report dated March 30, 2020 for the year ended December 31, 2019 filed with the SEC on April 2, 2020, as amended by Amendment #1 filed with the SEC on April 2, 2020 (as so amended, the “20-F”);
- (b) Our Material Change Report dated April 29, 2020 which was included as Exhibit 99.1 to the Form 6-K filed with the SEC on April 29, 2020;
- (c) Our Material Change Report dated April 30, 2020 which was included as Exhibit 99.1 to the Form 6-K filed with the SEC on April 30, 2020;

- (d) Our Material Change Report dated May 13, 2020 which was included as Exhibit 99.1 to the Form 6-K filed with the SEC on June 9, 2020;
- (e) Our Material Change Report dated May 27, 2020 which was included as Exhibit 99.1 to the Form 6-K filed with the SEC on June 3, 2020;
- (f) Our Material Change Report dated June 4, 2020 which was included as Exhibit 99.1 to the Form 6-K filed with the SEC on June 4, 2020;
- (g) Our Unaudited Condensed Interim Financial Statements for the three month period ended March 31, 2020, which were included as Exhibit 99.2 to the Form 6-K filed with the SEC on May 14, 2020, and Amendment No. 1 to Form 6-K filed with the SEC on May 15, 2020;
- (h) Our Management Discussion and Analysis for the three month period ended March 31, 2020, which was included as Exhibit 99.3 to the Form 6-K filed with the SEC on May 14, 2020, and Amendment No. 1 to Form 6-K filed with the SEC on May 15, 2020; and
- (i) Our management information circular for the annual general meeting of shareholders held on May 29, 2019, which was included as Exhibit 99.1 to the Form 6-K filed with the SEC on May 30, 2019.

PROSPECTUS SUPPLEMENT SUMMARY

This summary highlights certain information about us, the Offering and information appearing elsewhere in this Prospectus Supplement and in the documents, we incorporate by reference in this Prospectus Supplement. This summary is not complete and does not contain all of the information that you should consider before investing in the Shares we are offering. After you read this summary, to fully understand our company and the Offering and its consequences to you, you should read this entire Prospectus Supplement carefully, including the information referred to under the heading "Risk Factors" in this prospectus beginning on page S-15 and any related free writing prospectus as well as the other documents that we incorporate by reference into this prospectus including our financial statements and the exhibits to the Registration Statement of which this Prospectus Supplement is a part.

Titan Medical Inc. Overview

We are an Ontario corporation, being the successor corporation formed pursuant to an amalgamation under the *Business Corporations Act* (Ontario) on July 28, 2008. We are focused on the design and development of a robotic surgical system for application in MIS.

Our single-port robotic surgical system, currently under development, includes a surgeon-controlled robotic platform that incorporates a 3D high-definition vision system and multi-articulating instruments for performing MIS procedures through a single incision. The surgical system also includes a surgeon workstation that provides a surgeon with an advanced ergonomic interface to the robotic platform for controlling the instruments and viewing the inside of a patient's body in 3D during MIS procedures. The Company intends to initially pursue gynecologic surgical indications for use of its single-port robotic surgical system.

Our head and registered office is located at 155 University Avenue, Suite 750, Toronto, Ontario M5H 3B7. Our main telephone number is (416) 548-7522. Our corporate website is www.titanmedicalinc.com. Information contained on our website is not part of this Prospectus Supplement nor is it incorporated by reference herein.

Recent Developments for Titan Medical Inc

Nasdaq Notification

On November 27, 2019, we received notifications by Nasdaq that we were not in compliance with Nasdaq Listing Rule 5550(a)(2) since the closing bid price for our Common Shares listed on Nasdaq was below \$1.00 for 30 consecutive business days (the "**Minimum Bid Price**"), and Nasdaq Rule 5550(b)(2) since the Market Value of Listed Securities for our Common Shares listed on Nasdaq was below \$35 million for 30 consecutive business days (the "**Minimum MVLS**"). Nasdaq Rules further provided us with a period of 180 calendar days from the date of notification to regain compliance with the above noted Rules. While the period to regain compliance with the Minimum Bid Price has been tolled due to coronavirus, giving us until August 10, 2020 to cure the Minimum Bid Price deficiency, the period to regain compliance with the Minimum MVLS has not been tolled.

On May 26, 2020, we received a Staff Delisting Determination letter (the “**Determination**”) from Nasdaq setting forth a determination to delist our Common Shares from Nasdaq as a result of our failure to comply with the Minimum MVLS (the “**Deficiency**”). We appealed the Determination by requesting a hearing before a Hearings Panel (the “**Panel**”). The hearing request has stayed the delisting of our Common Shares until a determination is made by the Panel. The Common Shares will continue to trade on Nasdaq pending the outcome of the hearing before the Panel. We will address the ongoing non-compliance matters before the Panel and will request additional time to cure the Deficiency. There can be no assurance that, following the hearing, the Panel will grant our request for additional time to regain compliance with the Minimum MVLS, Minimum Bid Price or other continued listing requirements under Nasdaq Rules (the “**Continued Listing Requirements**”). If the Panel does not grant our request for additional time to comply, our Common Shares will be subject to delisting from Nasdaq. If our Common Shares were to be delisted by Nasdaq, the market liquidity of our Common Shares could be adversely affected and the market price of our Common Shares could decline, even though such Common Shares may continue to be traded “over-the-counter” and will continue to trade on the TSX. See “Risk Factors” for more information.

Naglireiter Litigation

On October 16, 2019, we became involved in litigation with Naglireiter Consulting, LLC (“**Naglireiter**”) when it filed a Complaint in the U.S. District Court for the Southern District of Florida (Case No. 0:19-cv-62574), alleging that we had not paid the amounts owed under several invoices and, further, that the invoices totaled approximately \$5 million. Naglireiter had been engaged by us to develop devices associated with our robotic surgical system, in particular, focusing on aspects of the instrumentation and the camera system.

On December 5, 2019, we filed an Answer, Affirmative Defenses and Counterclaim denying the allegations, asserting defenses to the Complaint, and asserting counterclaims against Naglireiter for (i) breach of contract including that the services that were rendered by Naglireiter were not rendered in a satisfactory manner and that Naglireiter failed to return property paid for by us, (ii) fraudulent inducement, (iii) negligent misrepresentation, (iv) indemnification and (v) conversion for refusing to return our property.

On February 13, 2020, Naglireiter filed an Amended Complaint against us to add a complaint of unjust enrichment alleging that Naglireiter had conferred benefits on us without our paying fair market value for them and asked the courts for a constructive trust over certain property of ours in Naglireiter’s possession.

On March 9, 2020, we filed an Answer and Affirmative Defenses to the Amended Complaint and an Amended Counterclaim, denying the allegations, asserting defenses to the Amended Complaint, and bringing additional counterclaims of (i) replevin to recover possession of personal property held by Naglireiter, (ii) civil theft for depriving us of our right to certain property in Naglireiter’s possession and (iii) injunctive relief to have Naglireiter cease and desist the violation of confidentiality provisions in the parties’ agreements.

On June 8, 2020, we entered into a settlement agreement with Naglireiter whereby (i) we will pay a sum of U.S. \$1,050,000 to Naglireiter, (ii) Naglireiter will return certain personal property and related electronic data of Titan in its possession, (iii) and the pending litigation will be dismissed with prejudice. Under the terms of the settlement agreement, each party is responsible for its own costs, expenses and attorneys’ fees.

Development and License Arrangements with Medtronic and Senior Secured Loan

On June 3, 2020, we entered into a development and license agreement (the “**Development Agreement**”) with a U.S. affiliate of Medtronic plc (“**Medtronic**”) in connection with the development of robotic assisted surgical technologies and a separate license agreement (the “**License Agreement**”) with Medtronic in respect of certain of our already developed technologies.

The Development Agreement provides for the development of robotic assisted surgical technologies for use by both us and Medtronic in our respective businesses through the granting of certain licenses to the intellectual property developed thereunder. In addition to retaining certain rights to commercialize the developed technologies, we will be eligible to receive payments totaling up to U.S. \$31 million for Medtronic’s license to such technologies. The payments are to be provided as technology milestones are completed and verified, and are further particularized in the table below.

Milestone (1)	Deadline (2)	Payment (US\$)(3)
Milestone 1	Four (4) months from Development Start Date (4)	\$ 10,000,000
Milestone 2 (5)	Four (4) months from Development Start Date	-
Milestone 3	Six (6) months from the later of (a) receipt by us of Payment for Milestone 1, (b) receipt by us from Medtronic of Medtronic deliverables required for Milestone 3, and (c) receipt by us from Medtronic of confirmation of certain due diligence in respect of our deliverables for Milestone 1	\$ 10,000,000
Milestone 4	Four (4) months from the later of (a) receipt by us of Payment for Milestone 3, (b) receipt by us of Medtronic deliverables for Milestone 4, and (c) receipt by us from Medtronic of confirmation of certain due diligence in respect of our deliverables for Milestone 3	\$ 11,000,000 (6),(7)

Notes:

1. Milestone 1, Milestone 3 and Milestone 4 are each defined in the Development Agreement and consist of the completion of the development of certain robotic assisted surgical technologies as described in the Development Agreement.
2. All as further described and qualified in the Development Agreement.
3. Each payment is conditional upon the corresponding milestone being completed on a timely basis.
4. "Development Start Date" has the meaning ascribed to it in the Development Agreement.
5. Milestone 2 is a non-technology milestone defined as our raising at least U.S. \$18,000,000 of capital between the effective date of the Development Agreement and the date that is four months from the Development Start Date.
6. The amount of the payment will be the sum of U.S. \$10,000,000 and the amount of certain legal, transaction and intellectual property related expenses to be paid to us up to a maximum of U.S. \$1,000,000 pursuant to the Development Agreement and License Agreement.
7. The balance outstanding under the Medtronic Loan (described below) will be offset against the payment for Milestone 4.

The Development Agreement provides that a steering committee comprising an equal number of representatives from Titan and Medtronic shall be established to provide oversight regarding the work toward achievement of the milestones. Either party may terminate the agreement if the other party materially breaches the agreement and (if the breach is curable) fails to cure the breach within forty (40) business days after receipt of written notice.

Under the terms of the License Agreement, we have granted Medtronic an exclusive license with regard to certain robotic assisted surgical technologies for an upfront royalty payment of U.S. \$10 million to be paid to us by Medtronic. We have retained certain rights to the licensed technologies to continue to develop and commercialize those technologies for our own business in single-port robotic assisted surgery.

On April 28, 2020, we received gross proceeds of \$1.5 million from a senior secured loan (the "**Medtronic Loan**") provided by an affiliate of Medtronic plc ("**Medtronic Lender**"). The Medtronic Loan is evidenced by an amended and restated senior secured promissory note ("**Note**") dated June 3, 2020, in the principal amount of \$1.5 million plus an amount equal to certain legal, transaction and intellectual property related expenses incurred by Medtronic pursuant to the Medtronic Agreements and will bear interest at the rate of 8% per annum. The unpaid principal balance owing under the Note, together with any accrued and unpaid interest and all other unpaid obligations under the Note, shall be due and payable in full on the earliest to occur of: (i) June 4, 2023, (ii) the completion of the last milestone under the Development Agreement, or (iii) a Change of Control (as defined in the Note), subject to an accelerated due date under certain adverse conditions. Until repayment of the loan, Medtronic may have one non-voting observer attend meetings of our Board of Directors.

We have entered into a security agreement in favor of Medtronic Lender (the "**Security Agreement**") pursuant to which we have granted to Medtronic Lender a security interest in all of our present and future property including all personal property, inventory, equipment and intellectual property. In addition, Medtronic Lender's rights and powers under the Security Agreement include without limitation (a) exercising and enforcing all rights and remedies of a holder of collateral as if Medtronic Lender were the absolute owner of the collateral, (b) collection of any proceeds arising in respect of all of our property pledged as security for the loan, (c) license or sublicense, whether on an exclusive or nonexclusive basis, of any of our intellectual property for such term and on such conditions and in such manner as Medtronic Lender in its sole judgment determines (taking into account such provisions as may be necessary to protect and preserve such intellectual property), and (d) the right to enforce its security in the event of a default which may include the appointment of a receiver by instrument or order of the court.

Changes to our Board of Directors

Charles Federico, who had served as our Chairman since May 2019, and John Schellhorn, who served as a director of Titan since June 2017, tendered their resignations from Titan's board of directors on June 3, 2020. Following the resignations, our board of directors consists of David McNally (Chief Executive Officer), John Barker and Stephen Randall, Chief Financial Officer. David McNally was appointed as Chairman of our board of directors on June 4, 2020. As a result of the resignations of the two independent directors, we do not currently meet the requirements of Nasdaq Listing Rule 5605(c)(2), which requires us to have an audit committee with three independent members. We are currently engaged in a plan to cure this deficiency.

Formation of U.S. subsidiary

On May 29, 2020, we incorporated Titan Medical USA, Inc., as a wholly-owned subsidiary of Titan, under the General Corporation Law of the State of Delaware.

2020 Financings

Aspire Capital

From January 3, 2020 to May 13, 2020, we raised \$2,071,930 through the sale of 4,408,048 Common Shares to Aspire Capital Fund, LLC ("**Aspire Capital**") in accordance with the terms of a common share purchase agreement ("**Second Aspire Agreement**") with Aspire Capital dated December 23, 2019, under which Aspire Capital committed to purchase up to \$35.0 million of Common Shares at our request from time to time, until June 23, 2022, subject to the terms and conditions of the agreement.

Cambridge Design Partnership Ltd.

On January 3, 2020, Cambridge Design Partnership Ltd. ("**Cambridge**") agreed to purchase from us 501,148 Common Shares at a price of \$0.50 per Share and the purchase price was satisfied by way of Cambridge setting off \$250,574 owing by us to Cambridge for services rendered by Cambridge.

March 2020 Financing

On March 27, 2020, we completed an offering of 7,000,000 Common Shares and 3,500,000 Common Share purchase warrants (each, a "**March 2020 Warrant**"), resulting in total gross proceeds of \$1,190,000 (\$862,294 net of closing cash costs including cash commission described below). Each March 2020 Warrant was exercisable to purchase one Common Share (a "**March 2020 Warrant Share**") at an exercise price of \$0.19 per Common Share for a period of five years following the date of closing of the offering.

In addition to the cash commission paid to Wainwright of \$83,300, broker warrants were issued to Wainwright which entitle the holder to purchase 490,000 Common Shares at a price of \$0.2125 per share prior to expiry on March 27, 2025.

Senior Secured Loan from Global Medical Technology Company

On April 28, 2020, we received gross proceeds of \$1.5 million from a senior secured loan provided by a leading global medical technology company (the "**Corporate Lender**") evidenced by an 8% \$1.5 million senior secured promissory note ("**Note**") and a security agreement (the "**Security Agreement**") executed and delivered by us in favor of the Corporate Lender. The Note matures on April 28, 2023 and the unpaid principal balance owing under the Note, together with any accrued and unpaid interest and all other unpaid obligations under the Note, shall be due and payable in full on the earliest to occur of: (i) April 28, 2023, (ii) a Change of Control (as defined in the Note), or (iii) a Qualified Financing (as defined in the Note) subject to an accelerated due date under certain adverse conditions.

The Security Agreement grants a security interest in all of our present and future property including all personal property, inventory, equipment and intellectual property to the Corporate Lender. In addition, the Corporate Lender's rights and powers include without limitation (a) exercising and enforcing all rights and remedies of a holder of collateral as if the Corporate Lender were the absolute owner of the collateral, (b) collection of any proceeds arising in respect of all of our property pledged as security for the loan, (c) license or sublicense, whether on an exclusive or nonexclusive basis, of any of our intellectual property for such term and on such conditions and in such manner as the Corporate Lender in its sole judgment determines (taking into account such provisions as may be necessary to protect and preserve such intellectual property), and (d) the right to enforce its security in the event of a default which may include the appointment of a receiver by instrument or order of the court.

May 2020 Financing

On May 6, 2020, we completed an offering of 5,514,504 Common Shares of the Company at a price of \$0.36268 per Common Share and 2,757,252 unregistered Common Share purchase warrants (each, a “May 2020 Warrant”), resulting in total gross proceeds of \$2,000,000 (\$1,613,800 net of estimated closing cash costs including cash commission described below). Each May 2020 Warrant is exercisable to purchase one Common Share at an exercise price of \$0.3002 per Common Share for a period of five and one-half (5.5) years following the date of closing of the offering.

In addition to the cash commission paid to Wainwright of \$140,000, broker warrants were issued to Wainwright which entitle the holder to purchase 386,015 Common Shares at a price of \$0.4534 per share prior to expiry on November 6, 2025.

June Warrants Exercised

On June 4, 2020, 900,000 warrants were exercised for gross proceeds of \$171,000.

THE OFFERING

Securities Offered	6,500,000 Common Shares, 11,500,000 Pre-Funded Warrants, and Common Warrants to purchase 9,000,000 Common Shares.
Description of Common Warrants	Each Warrant is exercisable to purchase one Common Share at an exercise price of \$1.00 per Warrant Share for a period of 4 years following the Closing Date.
Description of Pre-Funded Warrants	If the issuance of Common Shares to a purchaser in the Offering would result in such purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our Common Shares following the consummation of the Offering, then such purchaser may purchase, if they so choose, in lieu of the Common Shares that would result in such excess ownership, a Pre-Funded Warrant to purchase Pre-Funded Warrant Shares and one-half Common Warrant. Each Pre-Funded Warrant will have an exercise price of \$0.0001 per Pre-Funded Warrant Share, will be exercisable upon issuance and will expire when exercised in full.
Common Shares to be issued under the Offering	18,000,000 Common Shares assuming no exercise of the Common Warrants issued in the Offering and the full exercise of the Pre-Funded Warrants issued in the Offering. The total Common Shares to be issued and outstanding after completion of the Offering will be 78,831,381. ⁽¹⁾
Manner of offering	See “Plan of Distribution.”
Use of proceeds	We intend to use the net proceeds from the sale of the Securities under the Offering for general corporate purposes including: resuming the development of our single-port robotic surgical system, instruments and accessories; funding working capital (including the reduction of outstanding payables); and capital expenditures.
Trading symbols	Our Common Shares are listed on the TSX under the symbol “TMD” and the Nasdaq under the symbol “TMDI”.
Risk Factors	Investing in our Common Shares involves a high degree of risk. See “Risk Factors” beginning on page S-15 of this Prospectus Supplement for a discussion of factors you should consider carefully when making an investment decision.

- (1) The number of Common Shares to be outstanding immediately after completion of the Offering as shown above is based on 60,831,381 Common Shares outstanding as of June 8, 2020 and assumes the full exercise of the Pre-Funded Warrants. Unless otherwise indicated, the number of Common Shares presented in this Prospectus Supplement excludes:
- 1,272,931 Common Shares issuable upon the exercise of 886,144 Canadian dollar denominated options with a weighted average exercise price of CDN \$5.74 and 386,787 US dollar denominated options with a weighted average exercise price of \$3.19 as at June 4, 2020; and
 - 23,960,663 Common Shares issuable upon the exercise of warrants having a weighted-average exercise price of \$5.71 per warrant as at June 8, 2020. Unless otherwise stated, all information in this Prospectus Supplement assumes no exercise of the Common Warrants or the Placement Agent Warrants.

RISK FACTORS

Investing in our securities is speculative and involves a high degree of risk. You should carefully consider the risks set out below and the other documents incorporated by reference in this Prospectus Supplement that summarize the risks that may materially affect us and our business before making an investment in the Securities. Please see “*Documents Incorporated by Reference*”. If any of these risks occur, our business, results of operations or financial condition could be materially adversely affected. In that case, the trading price of our securities could decline, and you may lose all or part of your investment. The risks set out in this Prospectus Supplement are not the only risks we face. You should also refer to the other information set forth in this Prospectus Supplement as well as those incorporated by reference herein and therein, including financial statements and the related notes, for further risks faced by us.

There can be no assurance that the Offering will be completed.

The completion of the Offering is subject to the completion of definitive binding documentation and satisfaction of a number of conditions. There can be no certainty or guarantee that the Offering will be completed.

There is no guarantee that our Common Shares will earn any positive return in the short term or long term.

Investment in our Shares is speculative and involves a high degree of risk and should be undertaken only by holders whose financial resources are sufficient to enable them to assume such risks and who have no need for immediate liquidity in their investment, and who have the capacity to absorb a loss of some or all of their investment in our Shares.

Our Common Share price will fluctuate and your investment in our Shares could decrease in value.

Fluctuations in the market price or liquidity of Common Shares may harm the value of your investment in our Shares. You may not be able to resell your Shares at or above the price you pay under the Offering due to fluctuations in the market price caused by changes in our operations or prospects and other factors, including:

- actual or anticipated fluctuations in our operating results or future prospects;
- public reaction to our press releases, our other public announcements and our filings with the SEC;
- strategic actions by our management or by our competitors;
- changes in financial markets or general economic conditions;
- our ability to raise additional capital as needed;

- developments regarding our patents or proprietary rights;
- changes in stock market analyst recommendations or earnings estimates regarding our Common Shares, other comparable companies or our industry generally; and
- continuing volatility in the equity markets in general, and the price of our Common Shares, due to the effects and uncertainty of the coronavirus pandemic.

Future sales of our Shares could adversely affect the market price and our future capital-raising activities could involve the issuance of equity securities, which would dilute your investment and holdings, and could result in a decline in the trading price of our Common Shares.

We are likely to issue and sell securities, including Shares, if and when conditions are favorable, even if we may not have an immediate need for additional capital at that time. Sales of substantial amounts of Shares, or the perception that such sales could occur, could adversely affect the prevailing market price of our Common Shares and our ability to raise capital. We may issue additional Shares in future financing transactions or as incentive compensation for our executive management and other key personnel, consultants and advisors. Issuing any equity securities would be dilutive to the equity interests represented by our then-outstanding Common Shares. The market price for our Common Shares could decrease as the market takes into account the dilutive effect of any of these issuances.

We may lose our status as a foreign private issuer.

In order to maintain our status as a foreign private issuer, a majority of our Shares must be either directly or indirectly owned by non-residents of the U.S. unless we also satisfy one of the additional requirements necessary to preserve this status. We may in the future lose our foreign private issuer status if a majority of our Shares are held in the United States and if we fail to meet the additional requirements necessary to avoid loss of our foreign private issuer status. The regulatory and compliance costs under U.S. federal securities laws as a U.S. domestic issuer may be significantly more than the costs incurred as a Canadian foreign private issuer eligible to use the Multijurisdictional Disclosure System (the “MJDS”). If Titan is not a foreign private issuer, it would not be eligible to use the MJDS or other foreign issuer forms and would be required to file periodic and current reports and registration statements on U.S. domestic issuer forms with the SEC, which are more detailed and extensive than the forms available to a foreign private issuer. In addition, we may lose the ability to rely upon exemptions from Nasdaq corporate governance requirements that are available to foreign private issuers.

Titan is an “emerging growth company” and cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make it less attractive to investors.

Titan is an “emerging growth company” as defined in the JOBS Act. We will continue to qualify as an “emerging growth company” until the earliest to occur of: (a) the last day of the fiscal year during which Titan had total annual gross revenues of \$1,070,000,000 or more; (b) the last day of its fiscal year following the fifth anniversary of the date of the first sale of Titan’s common equity securities pursuant to an effective registration statement under the U.S. Securities Act; (c) the date on which Titan, during the previous 3-year period, issued more than \$1,000,000,000 in non-convertible debt; or (d) the date on which Titan is deemed to be a ‘large accelerated filer.’

For so long as Titan continues to qualify as an emerging growth company, it will be exempt from the requirement to include an auditor attestation report relating to internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act in its annual reports filed under the U.S. Exchange Act, even if it does not qualify as a “smaller reporting company,” as well as certain other exemptions from various reporting requirements that are applicable to other public companies.

There will be no market for the Warrants purchased under the Offering.

We have not applied and do not intend to apply to list the Warrants on any national securities exchange or a securities exchange in another jurisdiction. There will be no market through which the Warrants may be sold and purchasers may not be able to resell the Warrants. This may affect the pricing of the Warrants in the secondary market, the transparency and availability of trading prices, the liquidity of the Warrants, and the extent of issuer regulation.

The price of the Securities in the Offering (the “**Offering Price**”) has been determined by negotiations between Titan and the Placement Agent. The allocation of the Offering Price between the Shares and the Common Warrants and the Pre-Funded Warrants and Common Warrants, respectively, has been determined by Titan.

We will have broad discretion in how we use a portion of the net proceeds from the Offering, and we may use the net proceeds in ways in which you disagree.

You will be relying on the judgment of Titan’s management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that the net proceeds will be invested in a way that does not yield a favorable, or any, return for Titan. The failure of our management to use such funds effectively could have a material adverse effect on our business, financial condition, operating results and cash flow. See “Use of Proceeds.”

Titan is likely a “passive foreign investment company”, which may have adverse U.S. federal income tax consequences for U.S. investors.

Potential investors in the Securities who are U.S. taxpayers should be aware that Titan believes it was classified as a “passive foreign investment company” or “PFIC” during the tax year ended December 31, 2019, and may be a PFIC for the current tax year and future tax years. If the Company is a PFIC for any year during a U.S. taxpayer’s holding period of Shares, Common Warrants, Warrant Shares or Pre-Funded Warrants, then such U.S. taxpayer generally will be required to treat any gain realized upon a disposition of the Shares, Common Warrants, Warrant Shares or Pre-Funded Warrants or any so-called “excess distribution” received on its Shares, Pre-Funded Warrants, and Warrant Shares, as ordinary income, and to pay an interest charge on a portion of such gain or distribution. In certain circumstances, the sum of the tax and the interest charge may exceed the total amount of proceeds realized on the disposition, or the amount of excess distribution received, by the U.S. taxpayer. Subject to certain limitations, these tax consequences may be mitigated if a U.S. taxpayer makes a timely and effective QEF Election or a Mark-to-Market Election. Subject to certain limitations, such QEF Election may be made with respect to the Shares, Pre-Funded Warrants and Warrant Shares. Subject to certain limitations, such Mark-to-Market Election may be made with respect to the Shares and Warrant Shares. A U.S. taxpayer may not make a QEF Election with respect to the Common Warrants and may not make a Mark-to-Market Election with respect to the Common Warrants and Pre-Funded Warrants. A U.S. taxpayer who makes a timely and effective QEF Election generally must report on a current basis its share of the Company’s net capital gain and ordinary earnings for any year in which the Company is a PFIC, whether or not the Company distributes any amounts to its shareholders. A U.S. taxpayer who makes the Mark-to-Market Election generally must include as ordinary income each year the excess of the fair market value of the Shares or Warrant Shares over the taxpayer’s basis therein. This paragraph is qualified in its entirety by the discussion below under the heading “Certain United States Federal Income Tax Considerations — Passive Foreign Investment Company Rules.” Each potential investor who is a U.S. taxpayer should consult its own tax advisor regarding the tax consequences of the PFIC rules and the acquisition, ownership, and disposition of the Securities.

We may be delisted from Nasdaq if we do not satisfy continued listing requirements.

On November 27, 2019, we received notifications by Nasdaq that we were not in compliance with Nasdaq Listing Rule 5550(a)(2) since the closing bid price for our Common Shares listed on Nasdaq was below the \$1.00 Minimum Bid Price for 30 consecutive business days, and Nasdaq Rule 5550(b)(2) since the Market Value of Listed Securities for our Common Shares listed on Nasdaq was below the \$35 million Minimum MVLS for 30 consecutive business days. Nasdaq Rules further provided us with a period of 180 calendar days from the date of notification to regain compliance with the above noted Rules. While the period to regain compliance with the Minimum Bid Price has been tolled due to coronavirus, giving us until August 10, 2020 to cure the Minimum Bid Price deficiency, the period to regain compliance with the Minimum MVLS has not been tolled.

On May 26, 2020, we received a Staff Delisting Determination letter from Nasdaq setting forth a determination to delist our Common Shares from Nasdaq as a result of our failure to comply with the Minimum MVLS. We have appealed the Determination by requesting a hearing before a Hearings Panel. The hearing request has stayed the delisting of our Common Shares until a determination is made by the Panel. The Common Shares will continue to trade on Nasdaq pending the outcome of the hearing before the Panel. We will address the ongoing non-compliance matters before the Panel and will request additional time to cure the Deficiency. There can be no assurance that, following the hearing, the Panel will grant our request for additional time to regain compliance with the Minimum MVLS, Minimum Bid Price or other Continued Listing Requirements. If the Panel does not grant our request for additional time to comply, our Common Shares will be subject to delisting from Nasdaq.

If our Common Shares were to be delisted by Nasdaq, the market liquidity of our Common Shares could be adversely affected and the market price of our Common Shares could decline, even though such Common Shares may continue to be traded “over-the-counter” and will continue to trade on the TSX. See “*Risk Factors*” for more information.

Our operations have been affected by the outbreak of the coronavirus.

We are being affected by a pandemic outbreak of an infectious strain of the disease known as COVID-19 or coronavirus. Our operations have been adversely affected to the extent that the coronavirus has harmed the world economy in general and the capital markets in North America in particular. Our operations have experienced disruptions, including the temporary closure of our offices, which may materially and adversely affect our business, financial condition and operational results. The duration of the business disruption and related financial impact cannot be reasonably estimated at this time but may materially affect our ability to operate our business and result in additional costs as such disruptions continue. Such events could impair our ability to raise necessary capital, cause us to incur additional expenses or disrupt the services of our external engineering and medical technology development and manufacturing firms, as well as service providers. The extent to which the coronavirus or other health epidemic may impact our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others.

The global pandemic creates substantial uncertainty as to the willingness and ability of hospitals, HMOs, ambulatory care facilities and other prospective customers to purchase and implement robotic surgical systems.

The American College of Surgeons has called for hospitals to minimize, postpone or cancel elective procedures until the coronavirus outbreak slows down. An elective surgical procedure slowdown in the robotic surgical space may result in a substantial negative impact on the market prospects for robotic surgical systems and instruments and related services.

There can be no assurance that we will be able to secure and restore relationships with our suppliers and development partners.

The future success of the Company is substantially dependent on funding its research and development program and maintaining the support of its research and development and manufacturing service providers and, in some cases, securing new suppliers and service providers. There can be no assurance that we will be successful in accomplishing any of these goals.

We may not be able to raise sufficient financing on a timely basis.

Even if the Offering is completed, we may not be able to continue to raise sufficient financing on a timely basis in order to allow us to maintain product development and regulatory activities at a pace that would allow accomplishment of our previously stated milestones.

The Company may face cyber-security risks and threats.

Threats to information technology systems associated with cyber-security risks and cyber incidents or attacks continue to grow. It is possible that our business, financial and other systems or those of the companies, service providers or consultants with which we do business could be compromised, which might not be noticed for some period of time. Risks associated with these threats include, among other things, loss of intellectual property, disruption of business operations and safety procedures, loss or damage to worksite data delivery systems, and increased costs to prevent, respond to or mitigate cyber-security events.

The Loan Facility may limit or preclude us from arranging further debt financing. Under the terms of the Senior Secured Loan and related Security Agreement, the Corporate Lender has certain rights and powers that, if exercised, would have a material adverse effect on our business.

Due to the senior ranking of the Corporate Lender's security interest in all of our assets under the Security Agreement, we may be limited in, or entirely precluded from, granting a security interest in our assets in support of any further debt financing we may seek from any other lender. In the event that we seek further debt financing and it is not available due to our assets being pledged under the Security Agreement to the Corporate Lender, we will need to seek financing by way of equity financing and there is no assurance that any further equity financing will be available or available on terms acceptable to us.

If certain events of default as defined in the Note issued by us to the Corporate Lender were to occur, the Corporate Lender has the power to demand payment in full of the principal, interest and any other amounts owing under the Note and under the Security Agreement to take certain actions such as taking control of our assets including our intellectual property and if this were to happen, this may result in a disruption of our business and operations and we may lose our rights to our intellectual property and other assets. If we were to lose our intellectual property rights, we would effectively be forced to cease our current business operations.

We have a working capital deficiency of approximately \$5.4 million as at June 8, 2020 and a substantial portion of the net proceeds of the Offering may be used to pay our current liabilities. We will need to raise additional funds to carry on our business through to commercialization.

Our current liabilities exceed our current assets and we do not have sufficient funds to carry on our business or pay our liabilities. A substantial portion of the proceeds of the Offering may be used to pay our liabilities and we will need to raise further funds in order to carry on our business of robotic assisted surgical technology including our work in connection with our agreements with Medtronic. We may seek to raise up to all of the additional funds required to carry on our business through further equity offerings and if that were to happen, it may result in further dilution to existing stockholders. There is no assurance that any further financing will be available on terms acceptable to us or at all. If further financing is not available to us on terms acceptable to us or at all, any of our unpaid creditors may take a number of actions against us including commencing proceedings to recover the amounts we owe them and failing our ability to pay our creditors, they may take steps to enforce their security which may include placing the Company into receivership or bankruptcy and in such event, there is no assurance that our stockholders would receive any amounts in respect of their securities. Furthermore, there is no assurance that we will accept any financing offered to us if we deem the terms of the financing (including the sufficiency and timing of the financing) to be such that the financing would not be in our best interests.

There is no assurance that we will receive certain payments from Medtronic pursuant to our Development and Licensing Agreement with Medtronic. Our agreements with Medtronic provide Medtronic with certain rights to our existing intellectual property as well as intellectual property rights to certain technology to be developed under the agreements.

Our entitlement to receive up to \$31 million pursuant to our Development and Licensing Agreement with Medtronic is conditional upon the completion of certain technology development milestones set forth in the agreement. The technology development described in each of Milestones 1, 3 and 4 involves complex electromechanical design and development and there is no assurance that the milestones will be satisfied on a timely basis or at all. The technology design and development requires a combination of personnel with experience and expertise in robotic assisted surgical technology and financial resources. The Company will also need to re-engage its existing contractors and suppliers and certain additional contractors and suppliers and there is no assurance that those parties will all be agreeable to re-engage on terms satisfactory to the Company or at all. The Company may require additional financing beyond the proceeds of the Offering in order to carry out work in order to satisfy the technology development milestones and there is no assurance that additional financing will be available on terms satisfactory to the Company or at all.

Pursuant to the Development and Licensing Agreement, Medtronic holds certain intellectual property rights to certain technology to be developed under the agreement. Under the terms of the License Agreement, we have granted Medtronic an exclusive license with regard to certain previously developed robotic assisted surgical technologies while we have retained certain rights to the licensed technologies to continue to develop and commercialize those technologies for our own business in single-port robotic assisted surgery. As one of the world's leading medical device companies, Medtronic has substantially greater human and financial resources than we do and it may be in a position to develop and commercialize its robotic system earlier and superior to our system under development. This may pose a competitive threat to our business and if successful, Medtronic's introduction of its robotic system in the market may result in a material adverse effect on our business and prospects.

USE OF PROCEEDS

We estimate that the net proceeds from this Offering will be approximately \$16.4 million, after deducting the placement agent fees and estimated offering expenses payable by us, and assuming the sale of all of the Securities offered hereby.

We intend to use the net proceeds from the sale of the Securities under the Offering for general corporate purposes including: resuming the development of our single-port robotic surgical system, instruments and accessories; funding working capital (including the reduction of outstanding payables); and capital expenditures.

All expenses relating to the Offering, including fees paid to the Placement Agent, will be paid out of the gross proceeds of the Offering.

DESCRIPTION OF THE SECURITIES

We are offering 6,500,000 Common Shares, 11,500,000 Pre-Funded Warrants and 9,000,000 Common Warrants. The Common Shares, Pre-Funded Warrants and Common Warrants will be sold in fixed combinations at an offering price of \$1.00, consisting of one Common Share and one-half Common Warrant or one Pre-Funded Warrant and one-half Common Warrant, with each whole Common Warrant exercisable to purchase one Common Share. In addition to qualifying the offer and issue of the Common Shares, Warrants and Warrant Shares, this Prospectus Supplement also qualifies the issue of Placement Agent Warrants and Placement Agent Shares.

Common Shares

The holders of Shares are entitled to receive notice of and to attend all annual and special meetings of our shareholders and to one vote in respect of each Share held at the record date for each such meeting. The holders of Shares are entitled, at the discretion of the Board, to receive out of any or all of our profits or surplus properly available for the payment of dividends, any dividend declared by the Board and payable by us on the Shares. The holders of the Shares will participate *pro rata* in any distribution of our assets upon liquidation, dissolution or winding-up or other distribution of our assets. Such participation will be subject to the rights, privileges, restrictions and conditions attached to any of our securities issued and outstanding at such time ranking in priority to the Shares upon our liquidation, dissolution or winding-up. Shares are issued on authorization and approval from the Board, from treasury without par value and only as fully paid and are non-assessable. Shares will only be issued through the book-based system administered by CDS in Canada and by DTC in the United States, except in limited circumstances.

Common Warrants

Duration and Exercise Price

Each Common Warrant offered hereby will have an exercise price equal to \$1.00 per Share. The Common Warrants will be immediately exercisable and may be exercised until the fourth anniversary of the issuance date. The exercise price and number of Shares issuable upon exercise is subject to appropriate adjustment in the event of dividends, stock splits, reorganizations or similar events affecting Common Shares and the exercise price. The Common Warrants will be issued separately from the Common Shares and Pre-Funded Warrants. The Common Warrants will be issued in certificated form only.

Exercisability

The Common Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of Shares purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of the Common Warrant to the extent that the holder would own more than 4.99% of the outstanding Common Shares immediately after exercise, except that upon at least 61 days' prior notice from the holder to us, the holder may increase the amount of beneficial ownership of outstanding Shares after exercising the holder's Common Warrants up to 9.99% of the number of shares of our Common Shares outstanding immediately after giving effect to the exercise. The exercise of Common Warrants, and the Company's obligation to issue the Common Warrant Shares, will not be effective or enforceable if the issuance of the Common Warrant Shares to the holder would result in the holder and its joint actors and affiliates holding greater than 9.99% of the outstanding Common Shares after giving effect to the exercise and issuance, without the holder having filed and cleared a Personal Information Form (in prescribed form) with the TSX.

Cashless Exercise

If, at the time a holder exercises its Common Warrants, a registration statement registering the issuance of Shares underlying the Common Warrants under the Securities Act is not then effective or available for the issuance of such Shares, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of Shares determined according to a formula set forth in the Common Warrant.

Fractional Shares

No fractional Shares will be issued upon the exercise of the Common Warrants.

Transferability

Subject to applicable laws, a Common Warrant may be transferred at the option of the holder upon surrender of the Common Warrant to us together with the appropriate instruments of transfer.

Right as a Shareholder

Except as otherwise provided in the Common Warrants or by virtue of the holder's ownership of Common Shares, such holder of Common Warrants does not have the rights or privileges of a holder of Common Shares, including any voting rights, until such holder exercises such holder's Common Warrants.

Fundamental Transaction

In the event of a fundamental transaction, as described in the Common Warrants and generally including any reorganization, recapitalization or reclassification of our Common Shares, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding Common Shares, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding Common Shares, the holders of the Common Warrants will be entitled to receive upon exercise of the Common Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Common Warrants immediately prior to such fundamental transaction.

We have not applied and do not intend to apply to list the Common Warrants on any national securities exchange or a securities exchange in another jurisdiction. There will be no market through which the Common Warrants may be sold and purchasers may not be able to resell the Common Warrants purchased in the Offering. This may affect the pricing of the Common Warrants in the secondary market, the transparency and availability of trading prices, the liquidity of the Common Warrants, and the extent of issuer regulation.

Common Warrant certificates will be exchangeable for new Common Warrant certificates of different denominations at 155 University Avenue, Suite 750, Toronto, Ontario, M5H 3B7. Prior to the exercise of their Common Warrants, holders of Common Warrants will not have any of the rights of holders of Common Shares. We may amend the Common Warrants without the consent of the holders of the Common Warrants, to cure any ambiguity, to cure, correct or supplement any defective or inconsistent provision, or in any other manner that will not prejudice the rights of the holders of outstanding Common Warrants, as a group.

Pre-Funded Warrants

Duration and Exercise Price

Each Pre-Funded Warrants offered hereby will have an initial exercise price per share equal to \$0.0001. The Pre-Funded Warrants will be immediately exercisable and will expire when exercised in full. The exercise price and number of Pre-Funded Warrant Shares issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our Common Shares and the exercise price.

Exercisability

The Pre-Funded Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of Pre-Funded Warrant Shares purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of the Pre-Funded Warrants to the extent that the holder would own more than 4.99% of the outstanding Common Shares immediately after exercise, except that upon at least 61 days' prior notice from the holder to us, the holder may increase the amount of beneficial ownership of outstanding stock after exercising the holder's Pre-Funded Warrants up to 9.99% of the number of Common Shares outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants and Ontario law and regulation. Purchasers of Pre-Funded Warrants in this offering may also elect prior to the issuance of the Pre-Funded Warrants to have the initial exercise limitation set at 9.99% of our outstanding Common Shares. The exercise of Pre-Funded Warrants, and the Company's obligation to issue the Pre-Funded Warrant Shares, will not be effective or enforceable if the issuance of the Pre-Funded Warrant Shares to the holder would result in the holder and its joint actors and affiliates holding greater than 9.99% of the outstanding Common Shares after giving effect to the exercise and issuance, without the holder having filed and cleared a Personal Information Form (in prescribed form) with the TSX.

Cashless Exercise

In lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of Shares determined according to a formula set forth in the Pre-Funded Warrants.

Transferability

Subject to applicable laws, a Pre-Funded Warrant may be transferred at the option of the holder upon surrender of the Pre-Funded Warrant to us together with the appropriate instruments of transfer.

Fractional Shares

No fractional Shares will be issued upon the exercise of the Pre-Funded Warrants. Rather, the number of Shares to be issued will be rounded to the nearest whole number.

Right as a Stockholder

Except as otherwise provided in the Pre-Funded Warrants or by virtue of such holder's ownership of Shares, the holders of the Pre-Funded Warrants do not have the rights or privileges of holders of our Common Shares, including any voting rights, until they exercise their Pre-Funded Warrants. The Pre-Funded Warrants will provide that holders have the right to participate in distributions or dividends paid on our Common Shares.

Fundamental Transaction

In the event of a fundamental transaction, as described in the Pre-Funded Warrants and generally including any reorganization, recapitalization or reclassification of our Common Shares, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding Common Shares, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding Common Shares, the holders of the Pre-Funded Warrants will be entitled to receive upon exercise of the Pre-Funded Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants immediately prior to such fundamental transaction.

We have not applied and do not intend to apply to list the Pre-Funded Warrants on any national securities exchange or a securities exchange in another jurisdiction. There will be no market through which the Pre-Funded Warrants may be sold and purchasers may not be able to resell the Pre-Funded Warrants purchased in the Offering. This may affect the pricing of the Pre-Funded Warrants in the secondary market, the transparency and availability of trading prices, the liquidity of the Pre-Funded Warrants, and the extent of issuer regulation.

Pre-Funded Warrant certificates will be exchangeable for new Pre-Funded Warrant certificates of different denominations at 155 University Avenue, Suite 750, Toronto, Ontario, M5H 3B7. Prior to the exercise of their Pre-Funded Warrants, holders of Pre-Funded Warrants will not have any of the rights of holders of Common Shares. We may amend the Pre-Funded Warrants without the consent of the holders of the Pre-Funded Warrants, to cure any ambiguity, to cure, correct or supplement any defective or inconsistent provision, or in any other manner that will not prejudice the rights of the holders of outstanding Pre-Funded Warrants, as a group.

Placement Agent Warrants

We have also agreed to issue to the Placement Agent in the Offering the Placement Agent Warrants to purchase up to 1,260,000 Common Shares, which represent 7.0% of the aggregate number of Common Shares and Pre-Funded Warrants sold in this Offering.

The material terms and provisions of the Placement Agent Warrants are substantially the same as the Warrants described above under the heading "Warrants," with the exception of the following terms:

- The exercise price of the Placement Agent Warrants is \$1.25 per share, which represents 125% of the offering price per Common Share and one-half Common Warrant combination in this Offering;
- The Placement Agent Warrants may be exercised until the fourth anniversary from the date of this Offering;
- The Beneficial Ownership Limitation is 4.99%; and
- The Placement Agent Warrants will not be transferable for 180 days from the date of effectiveness or the commencement of sales of this Offering, except in certain circumstances described in the Placement Agent Warrants. Following such period, subject to applicable laws, the Placement Agent Warrants may be transferred at the option of the holder upon surrender of a Placement Agent Warrant to us together with the appropriate instruments of transfer.

CERTAIN UNITED STATES FEDERAL TAX CONSIDERATIONS

The following is a general summary of certain U.S. federal income tax considerations applicable to a U.S. Holder (as defined below) arising from and relating to the acquisition, ownership and disposition of Common Shares acquired pursuant to this Prospectus Supplement, the exercise, disposition, and lapse of Common Warrants acquired as part of the Offering, and the acquisition, ownership, and disposition of Common Warrant Shares received upon exercise of the Common Warrants, the ownership, exercise and disposition of Pre-Funded Warrants acquired pursuant to this Prospectus Supplement and the Pre-Funded Warrant Shares received upon the exercise of the Pre-Funded Warrants.

This summary is for general information purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income tax considerations that may apply to a U.S. Holder as a result of the acquisition of Securities pursuant to this Offering. In addition, this summary does not take into account the individual facts and circumstances of any particular U.S. Holder that may affect the U.S. federal income tax consequences to such U.S. Holder, including specific tax consequences to a U.S. Holder under an applicable tax treaty. Accordingly, this summary is not intended to be, and should not be construed as, legal or U.S. federal income tax advice with respect to any particular U.S. Holder. This summary does not address the U.S. federal net investment income, U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences to U.S. Holders of the acquisition, ownership, and disposition of Securities. In addition, except as specifically set forth below, this summary does not discuss applicable tax reporting requirements. Each U.S. Holder should consult its own tax advisor regarding the U.S. federal, U.S. federal net investment income, U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership and disposition of Securities.

No opinion from legal counsel or ruling from the Internal Revenue Service (the "IRS") has been requested, or will be obtained, regarding the U.S. federal income tax considerations applicable to U.S. Holders as discussed in this summary. This summary is not binding on the IRS, and the IRS is not precluded from taking a position that is different from, and contrary to, the positions taken in this summary. In addition, because the authorities on which this summary is based are subject to various interpretations, the IRS and the U.S. courts could disagree with one or more of the positions taken in this summary.

Scope of this Summary

Authorities

This summary is based on the Internal Revenue Code of 1986, as amended (the "Code"), Treasury Regulations (whether final, temporary, or proposed) promulgated under the Code, published rulings of the IRS, published administrative positions of the IRS and U.S. court decisions, that are in effect and available, as of the date of this document. Any of the authorities on which this summary is based could be changed in a material and adverse manner at any time, and any such change could be applied retroactively. This summary does not discuss the potential effects, whether adverse or beneficial, of any proposed legislation that, if enacted, could be applied on a retroactive or prospective basis.

U.S. Holders

For purposes of this summary, the term "U.S. Holder" means a beneficial owner of Securities acquired pursuant to this Prospectus Supplement that is for U.S. federal income tax purposes:

- a citizen or individual resident of the United States;
- a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) organized under the laws of the United States, any state thereof or the District of Columbia;
- an estate whose income is subject to U.S. federal income taxation regardless of its source; or
- a trust that (1) is subject to the primary supervision of a court within the United States and the control of one or more U.S. persons for all substantial decisions or (2) has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person.

U.S. Holders Subject to Special U.S. Federal Income Tax Rules Not Addressed

This summary does not address the U.S. federal income tax considerations applicable to U.S. Holders that are subject to special provisions under the Code, including U.S. Holders that: (a) are tax-exempt organizations, qualified retirement plans, individual retirement accounts, or other tax-deferred accounts; (b) are financial institutions, underwriters, insurance companies, real estate investment trusts, or regulated investment companies; (c) are brokers or dealers in securities or currencies or U.S. Holders that are traders in securities that elect to apply a mark-to-market accounting method; (d) have a "functional currency" other than the U.S. dollar; (e) own Securities as part of a straddle, hedging transaction, conversion transaction, constructive sale, or other integrated transaction; (f) acquired Securities in connection with the exercise of employee stock options or otherwise as compensation for services; (g) hold Securities other than as a capital asset within the meaning of Section 1221 of the Code (generally, property held for investment purposes); (h) are partnerships and other pass-through entities (and investors in such partnerships and entities); (i) are subject to special tax accounting rules with respect to Securities; (j) own, have owned or will own (directly, indirectly, or by attribution) 10% or more of the total combined voting power or value of the Company's outstanding shares; (k) are U.S. expatriates or former long-term residents of the U.S., or (l) are subject to taxing jurisdictions other than, or in addition to, the United States. U.S. Holders that are subject to special provisions under the Code, including U.S. Holders described immediately above, should consult their own tax advisors regarding the U.S. federal, U.S. federal net investment income, U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership and disposition of Securities.

If an entity or arrangement that is classified as a partnership for U.S. federal income tax purposes holds Securities, the U.S. federal income tax consequences to such entity or arrangement and the owners of such entity or arrangement generally will depend on the activities of such entity or arrangement and the status of such owners. This summary does not address the tax consequences to any such entity or arrangement or owner. Owners of entities or arrangements that are classified as partnerships for U.S. federal income tax purposes should consult their own tax advisor regarding the U.S. federal income tax consequences arising from and relating to the acquisition, ownership, and disposition of Securities.

U.S. Federal Income Tax Consequences of the Acquisition of Shares and Warrants

The offering price of \$1.00 for each combination of a Common Share and one-half Common Warrant or a Pre-Funded Warrant and one-half Common Warrant will be allocated among the Common Share or the Pre-Funded Warrant and one-half Common Warrant in proportion to their relative fair market values at the time of purchase by the U.S. Holder. This allocation of the offering price will establish a U.S. Holder's initial tax basis for U.S. federal income tax purposes in the Common Share and one-half Common Warrant or Pre-Funded Warrant and one-half Common Warrant. For this purpose, we will allocate \$0.39 of the offering price to the Common Share, \$0.39 of the offering price to the Pre-Funded Warrant and \$0.61 of the offering price to the one-half Common Warrant.

The IRS will not be bound by such allocations of the offering price for the Common Shares, Pre-Funded Warrants and Common Warrants, and therefore, the IRS or a U.S. court may not respect the allocation set forth above. Each U.S. Holder should consult its own tax advisor regarding the allocation of the offering price.

Treatment of Pre-Funded Warrants

Although it is not entirely free from doubt, the Company believes a Pre-Funded Warrant should be treated as a separate class of common shares of the Company for U.S. federal income tax purposes and a U.S. Holder of Pre-Funded Warrants should generally be taxed in the same manner as a holder of Common Shares except as described below. Accordingly, no gain or loss should be recognized upon the exercise of a Pre-Funded Warrant and, upon exercise, the holding period of a Pre-Funded Warrant should carry over to the Pre-Funded Warrant Shares received. Similarly, the tax basis of the Pre-Funded Warrant should carry over to the Pre-Funded Warrant Shares received upon exercise, increased by the exercise price of \$0.0001 per share. However, such characterization is not binding on the IRS, and the IRS may treat the Pre-Funded Warrants as warrants to acquire Common Shares. If so, the amount and character of a U.S. Holder's gain with respect to an investment in Pre-Funded Warrants could change, and a U.S. Holder may not be entitled to make the "QEF Election" or "Mark-to-Market Election" described below to mitigate PFIC consequences in the event that the Company is classified as a PFIC. Accordingly, each U.S. Holder should consult its own tax advisor regarding the risks associated with the acquisition of a Pre-Funded Warrant pursuant to this Offering (including potential alternative characterizations). The balance of this discussion generally assumes that the characterization described above is respected for U.S. federal income tax purposes.

Passive Foreign Investment Company Rules

If the Company is considered a “passive foreign investment company” within the meaning of Section 1297 of the Code (a “PFIC”) at any time during a U.S. Holder’s holding period, the following sections will generally describe the potentially adverse U.S. federal income tax consequences to U.S. Holders of the acquisition, ownership, and disposition of Securities.

The Company believes that it was classified as a PFIC for the tax year ended December 31, 2019, and may be a PFIC in its current and future tax years. No opinion of legal counsel or ruling from the IRS concerning the status of the Company as a PFIC has been obtained or is currently planned to be requested. The determination of whether any corporation was, or will be, a PFIC for a tax year depends, in part, on the application of complex U.S. federal income tax rules, which are subject to differing interpretations. In addition, whether any corporation will be a PFIC for any tax year depends on the assets and income of such corporation over the course of each such tax year and, as a result, the Company’s PFIC status for the current year and future years cannot be predicted with certainty as of the date of this document. Accordingly, there can be no assurance that the IRS will not challenge any PFIC determination made by the Company. Each U.S. Holder should consult its own tax advisor regarding the Company’s status as a PFIC and the PFIC status of each non-U.S. subsidiary of the Company.

In any year in which the Company is classified as a PFIC, a U.S. Holder will be required to file an annual report with the IRS containing such information as Treasury Regulations and/or other IRS guidance may require. In addition to penalties, a failure to satisfy such reporting requirements may result in an extension of the time period during which the IRS can assess a tax. U.S. Holders should consult their own tax advisors regarding the requirements of filing such information returns under these rules, including the requirement to file an IRS Form 8621 annually.

The Company generally will be a PFIC for any tax year in which (a) 75% or more of the gross income of the Company for such tax year is passive income (the “PFIC income test”) or (b) 50% or more of the value of the assets of the Company either produce passive income or are held for the production of passive income, based on the quarterly average of the fair market value of such assets (the “PFIC asset test”). “Gross income” generally includes sales revenues less the cost of goods sold, plus income from investments and from incidental or outside operations or sources, and “passive income” generally includes, for example, dividends, interest, certain rents and royalties, certain gains from the sale of stock and securities, and certain gains from commodities transactions.

For purposes of the PFIC income test and PFIC asset test described above, if the Company owns, directly or indirectly, 25% or more of the total value of the outstanding shares of another corporation, the Company will be treated as if it (a) held a proportionate share of the assets of such other corporation and (b) received directly a proportionate share of the income of such other corporation. In addition, for purposes of the PFIC income test and PFIC asset test described above, “passive income” does not include any interest, dividends, rents, or royalties that are received or accrued by the Company from a “related person” (as defined in Section 954(d)(3) of the Code), to the extent such items are properly allocable to the income of such related person that is not passive income.

Under certain attribution rules, if the Company is a PFIC, U.S. Holders will be deemed to own their proportionate share of any of the Company’s subsidiaries which is also a PFIC (a “Subsidiary PFIC”), and will generally be subject to U.S. federal income tax under the “Default PFIC Rules Under Section 1291 of the Code” discussed below on their proportionate share of any (i) distribution on the shares of a Subsidiary PFIC and (ii) disposition or deemed disposition of shares of a Subsidiary PFIC, both as if such U.S. Holders directly held the shares of such Subsidiary PFIC. Accordingly, U.S. Holders should be aware that they could be subject to tax under the PFIC rules even if no distributions are received and no redemptions or other dispositions of Securities are made. In addition, U.S. Holders may be subject to U.S. federal income tax on any indirect gain realized on the stock of a Subsidiary PFIC on the sale or disposition of Securities.

Default PFIC Rules Under Section 1291 of the Code

If the Company is a PFIC, the U.S. federal income tax consequences to a U.S. Holder of the purchase of Common Shares, Warrants and Warrant Shares and the acquisition, ownership, and disposition of Securities will depend on whether such U.S. Holder makes a “qualified electing fund” or “QEF” election (a “**QEF Election**”) or makes a mark-to-market election under Section 1296 of the Code (a “**Mark-to-Market Election**”) with respect to Common Shares or Warrant Shares. A U.S. Holder that does not make either a QEF Election or a Mark-to-Market Election (a “**Non-Electing U.S. Holder**”) will be taxable as described below.

A Non-Electing U.S. Holder will be subject to the rules of Section 1291 of the Code with respect to (a) any gain recognized on the sale or other taxable disposition of Securities and (b) any excess distribution received on the Common Shares, Warrants and Warrant Shares. A distribution generally will be an “excess distribution” to the extent that such distribution (together with all other distributions received in the current tax year) exceeds 125% of the average distributions received during the three preceding tax years (or during a U.S. Holder’s holding period for the Common Shares, Warrants and Warrant Shares, if shorter).

Under Section 1291 of the Code, any gain recognized on the sale or other taxable disposition of Securities of a PFIC (including an indirect disposition of shares of a Subsidiary PFIC), and any excess distribution received on such Common Shares, Warrants and Warrant Shares (or a distribution by a Subsidiary PFIC to its shareholder that is deemed to be received by a U.S. Holder) must be ratably allocated to each day in a Non-Electing U.S. Holder’s holding period for the Common Shares, Warrants or Warrant Shares. The amount of any such gain or excess distribution allocated to the tax year of disposition or distribution of the excess distribution and to years before the entity became a PFIC, if any, would be taxed as ordinary income (and not eligible for certain preferential tax rates, as discussed below). The amounts allocated to any other tax year would be subject to U.S. federal income tax at the highest tax rate applicable to ordinary income in each such year, and an interest charge would be imposed on the tax liability for each such year, calculated as if such tax liability had been due in each such year. A Non-Electing U.S. Holder that is not a corporation must treat any such interest paid as “personal interest,” which is not deductible.

If the Company is a PFIC for any tax year during which a Non-Electing U.S. Holder holds Securities, it will continue to be treated as a PFIC with respect to such Non-Electing U.S. Holder, regardless of whether it ceases to be a PFIC in one or more subsequent tax years. If the Company ceases to be a PFIC, a Non-Electing U.S. Holder may terminate this deemed PFIC status with respect to Common Shares, Warrants and Warrant Shares by electing to recognize gain (which will be taxed under the rules of Section 1291 of the Code as discussed above) as if such Common Shares and Warrant Shares were sold on the last day of the last tax year for which the Company was a PFIC. No such election, however, may be made with respect to the Common Warrants.

Under proposed Treasury Regulations, if a U.S. holder has an option, warrant, or other right to acquire stock of a PFIC (such as the Common Warrants), such option, warrant or right is considered to be PFIC stock subject to the default rules of Section 1291 of the Code. Under rules described below, the holding period for the Common Warrant Shares will begin on the date a U.S. Holder acquires the Common Warrants. This will impact the availability of the QEF Election and Mark-to-Market Election with respect to the Common Warrant Shares. Thus, a U.S. Holder will have to account for Common Warrant Shares and Common Shares under the PFIC rules and the applicable elections differently.

QEF Election

A U.S. Holder that makes a QEF Election for the first tax year in which its holding period of its Common Shares or Pre-Funded Warrants begins generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to its Common Shares or Pre-Funded Warrants. However, a U.S. Holder that makes a QEF Election will be subject to U.S. federal income tax on such U.S. Holder’s pro rata share of (a) the Company’s net capital gain, which will be taxed as long-term capital gain to such U.S. Holder, and (b) the Company’s ordinary earnings, which will be taxed as ordinary income to such U.S. Holder. Generally, “net capital gain” is the excess of (a) net long-term capital gain over (b) net short-term capital loss, and “ordinary earnings” are the excess of (a) “earnings and profits” over (b) net capital gain. A U.S. Holder that makes a QEF Election will be subject to U.S. federal income tax on such amounts for each tax year in which the Company is a PFIC, regardless of whether such amounts are actually distributed to such U.S. Holder by the Company. However, for any tax year in which the Company is a PFIC and has no net income or gain, U.S. Holders that have made a QEF Election would not have any income inclusions as a result of the QEF Election. If a U.S. Holder that made a QEF Election has an income inclusion, such a U.S. Holder may, subject to certain limitations, elect to defer payment of current U.S. federal income tax on such amounts, subject to an interest charge. If such U.S. Holder is not a corporation, any such interest paid will be treated as “personal interest,” which is not deductible.

A U.S. Holder that makes a timely QEF Election generally (a) may receive a tax-free distribution from the Company to the extent that such distribution represents “earnings and profits” that were previously included in income by the U.S. Holder because of such QEF Election and (b) will adjust such U.S. Holder’s tax basis in the Common Shares or Pre-Funded Warrants to reflect the amount included in income or allowed as a tax-free distribution because of such QEF Election. In addition, a U.S. Holder that makes a QEF Election generally will recognize capital gain or loss on the sale or other taxable disposition of Common Shares or Pre-Funded Warrants.

The procedure for making a QEF Election, and the U.S. federal income tax consequences of making a QEF Election, will depend on whether such QEF Election is timely. A QEF Election will be treated as “timely” for purposes of avoiding the default PFIC rules discussed above if such QEF Election is made for the first year in the U.S. Holder’s holding period for the Common Shares or Pre-Funded Warrants in which the Company was a PFIC. A U.S. Holder may make a timely QEF Election by filing the appropriate QEF Election documents at the time such U.S. Holder files a U.S. federal income tax return for such year.

A QEF Election will apply to the tax year for which such QEF Election is made and to all subsequent tax years, unless such QEF Election is invalidated or terminated or the IRS consents to revocation of such QEF Election. If a U.S. Holder makes a QEF Election and, in a subsequent tax year, the Company ceases to be a PFIC, the QEF Election will remain in effect (although it will not be applicable) during those tax years in which the Company is not a PFIC. Accordingly, if the Company becomes a PFIC in another subsequent tax year, the QEF Election will be effective and the U.S. Holder will be subject to the QEF rules described above during any subsequent tax year in which the Company qualifies as a PFIC.

As discussed above, under proposed Treasury Regulations, if a U.S. holder has an option, warrant or other right to acquire stock of a PFIC (such as the Common Warrants), such option, warrant or right is considered to be PFIC stock subject to the default rules of Section 1291 of the Code. However, a U.S. Holder of an option, warrant or other right to acquire stock of a PFIC may not make a QEF Election that will apply to the option, warrant or other right to acquire PFIC stock. In addition, under proposed Treasury Regulations, if a U.S. Holder holds an option, warrant or other right to acquire stock of a PFIC, the holding period with respect to shares of stock of the PFIC acquired upon exercise of such option, warrant or other right will include the period that the option, warrant or other right was held.

Consequently, under the proposed Treasury Regulations, if a U.S. Holder of Common Warrant Shares makes a QEF Election, such election generally will not be treated as a timely QEF Election with respect to Common Warrant Shares and the rules of Section 1291 of the Code discussed above will continue to apply with respect to such U.S. Holder’s Common Warrant Shares. However, a U.S. Holder of Common Warrant Shares should be eligible to make a timely QEF Election if such U.S. Holder makes a “purging” or “deemed sale” election to recognize gain (which will be taxed under the rules of Section 1291 of the Code discussed above) as if such Common Warrant Shares were sold for fair market value. As a result of the “purging” or “deemed sale” election, the U.S. Holder will have a new basis and holding period in the Common Warrant Shares acquired upon the exercise of the Common Warrants for purposes of the PFIC rules. In addition, gain recognized on the sale or other taxable disposition (other than by exercise) of the Common Warrants by a U.S. Holder will be subject to the rules of Section 1291 of the Code discussed above. Each U.S. Holder should consult its own tax advisor regarding the application of the PFIC rules to the Securities.

For each tax year that the Company qualifies as a PFIC, the Company: (a) intends to make available to U.S. Holders, upon their written request, a PFIC Annual Information Statement as described in Treasury Regulation Section 1.1295-1(g) (or any successor Treasury Regulation) and (b) upon written request, use commercially reasonable efforts to provide such additional information that such U.S. Holder is reasonably required to obtain in connection with maintaining such QEF Election with regard to the Company. The Company may elect to provide such information on its website. Each U.S. Holder should consult its own tax advisor regarding the availability of, and procedure for making, a QEF Election.

A U.S. Holder makes a QEF Election by attaching a completed IRS Form 8621, including a PFIC Annual Information Statement, to a timely filed U.S. federal income tax return. However, if the Company does not provide the required information with regard to the Company or any of its Subsidiary PFICs, U.S. Holders will not be able to make a QEF Election for such entity and will continue to be subject to the rules of Section 1291 of the Code discussed above that apply to Non-Electing U.S. Holders with respect to the taxation of gains and excess distributions.

Mark-to-Market Election

A U.S. Holder may make a Mark-to-Market Election with respect to Common Shares and Warrant Shares only if the Common Shares and Warrant Shares are marketable stock. The Common Shares and Warrant Shares generally will be “marketable stock” if the Common Shares and Warrant Shares are regularly traded on (a) a national securities exchange that is registered with the SEC, (b) the national market system established pursuant to Section 11A of the U.S. Exchange Act or (c) a foreign securities exchange that is regulated or supervised by a governmental authority of the country in which the market is located, provided that (i) such foreign exchange has trading volume, listing, financial disclosure, and other requirements and the laws of the country in which such foreign exchange is located, together with the rules of such foreign exchange, ensure that such requirements are actually enforced and (ii) the rules of such foreign exchange ensure active trading of listed stocks. If such stock is traded on such a qualified exchange or other market, such stock generally will be considered “regularly traded” for any calendar year during which such stock is traded, other than in *de minimis* quantities, on at least 15 days during each calendar quarter. Provided that the Common Shares and Warrant Shares are “regularly traded” as described in the preceding sentence, the Common Shares and Warrant Shares, are expected to be marketable stock. The Company believes that its Common Shares were “regularly traded” in the first calendar quarter of 2020. However, there can be no assurance that the Common Shares will be “regularly traded” in subsequent calendar quarters. U.S. Holders should consult their own tax advisors regarding the marketable stock rules. A Mark-to-Market Election will likely not be available with respect to the Pre-Funded Warrants and Common Warrants.

A U.S. Holder that makes a Mark-to-Market Election with respect to its Common Shares generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to such Common Shares. However, if a U.S. Holder does not make a Mark-to-Market Election beginning in the first tax year of such U.S. Holder’s holding period for the Common Shares and such U.S. Holder has not made a timely QEF Election, the rules of Section 1291 of the Code discussed above will apply to certain dispositions of, and distributions on, the Common Shares.

Any Mark-to-Market Election made by a U.S. Holder for the Common Shares will also apply to such U.S. Holder’s Warrant Shares. As a result, if a Mark-to-Market Election has been made by a U.S. Holder with respect to Common Shares, any Warrant Shares received will automatically be marked-to-market in the year of exercise. Because, under the proposed Treasury Regulations, a U.S. Holder’s holding period for Warrant Shares includes the period during which such U.S. Holder held the respective Warrants, a U.S. Holder will be treated as making a Mark-to-Market Election with respect to its Warrant Shares after the beginning of such U.S. Holder’s holding period for the Warrant Shares unless the Warrant Shares are acquired in the same tax year as the year in which the U.S. Holder acquired its respective Warrants. Consequently, the default rules under Section 1291 described above generally will apply to the mark-to-market gain realized in the tax year in which Warrant Shares are received. However, the general mark-to-market rules will apply to subsequent tax years.

A U.S. Holder that makes a Mark-to-Market Election will include in ordinary income, for each tax year in which the Company is a PFIC, an amount equal to the excess, if any, of (a) the fair market value of the Common Shares and any Warrant Shares, as of the close of such tax year over (b) such U.S. Holder’s tax basis in the Common Shares and any Warrant Shares. A U.S. Holder that makes a Mark-to-Market Election will be allowed a deduction in an amount equal to the excess, if any, of (i) such U.S. Holder’s adjusted tax basis in the Common Shares and any Warrant Shares, over (ii) the fair market value of such Common Shares and any Warrant Shares (but only to the extent of the net amount of previously included income as a result of the Mark-to-Market Election for prior tax years).

A U.S. Holder that makes a Mark-to-Market Election generally also will adjust such U.S. Holder's tax basis in the Common Shares and Warrant Shares to reflect the amount included in gross income or allowed as a deduction because of such Mark-to-Market Election. In addition, upon a sale or other taxable disposition of Common Shares and Warrant Shares, a U.S. Holder that makes a Mark-to-Market Election will recognize ordinary income or ordinary loss (not to exceed the excess, if any, of (a) the amount included in ordinary income because of such Mark-to-Market Election for prior tax years over (b) the amount allowed as a deduction because of such Mark-to-Market Election for prior tax years).

A U.S. Holder makes a Mark-to-Market Election by attaching a completed IRS Form 8621 to a timely filed U.S. federal income tax return. A timely Mark-to-Market Election applies to the tax year in which such Mark-to-Market Election is made and to each subsequent tax year, unless the Common Shares and Warrant Shares cease to be "marketable stock" or the IRS consents to revocation of such election. Each U.S. Holder should consult its own tax advisor regarding the availability of, and procedure for making, a Mark-to-Market Election.

Although a U.S. Holder may be eligible to make a Mark-to-Market Election with respect to the Common Shares and Warrant Shares, no such election may be made with respect to the stock of any Subsidiary PFIC that a U.S. Holder is treated as owning because such stock is not marketable. Hence, the Mark-to-Market Election will not be effective to eliminate the interest charge and other income inclusion rules described above with respect to deemed dispositions of Subsidiary PFIC stock or distributions from a Subsidiary PFIC to its shareholder.

Other PFIC Rules

Under Section 1291(f) of the Code, the IRS has issued proposed Treasury Regulations that, subject to certain exceptions, would cause a U.S. Holder that had not made a timely QEF Election to recognize gain (but not loss) upon certain transfers of Securities that would otherwise be tax-deferred (e.g., gifts and exchanges pursuant to corporate reorganizations). However, the specific U.S. federal income tax consequences to a U.S. Holder may vary based on the manner in which Securities are transferred.

If finalized in their current form, the proposed Treasury Regulations applicable to PFICs would be effective for transactions occurring on or after April 1, 1992. Because the proposed Treasury Regulations have not yet been adopted in final form, they are not currently effective, and there is no assurance that they will be adopted in the form and with the effective date proposed. Nevertheless, the IRS has announced that, in the absence of final Treasury Regulations, taxpayers may apply reasonable interpretations of the Code provisions applicable to PFICs and that it considers the rules set forth in the proposed Treasury Regulations to be reasonable interpretations of those Code provisions. The PFIC rules are complex, and the implementation of certain aspects of the PFIC rules requires the issuance of Treasury Regulations which in many instances have not been promulgated and which, when promulgated, may have retroactive effect. U.S. Holders should consult their own tax advisors about the potential applicability of the proposed Treasury Regulations.

Certain additional adverse rules will apply with respect to a U.S. Holder if the Company is a PFIC, regardless of whether such U.S. Holder makes a QEF Election. For example under Section 1298(b)(6) of the Code, a U.S. Holder that uses Securities as security for a loan will, except as may be provided in Treasury Regulations, be treated as having made a taxable disposition of such Securities.

In addition, a U.S. Holder who acquires Securities from a decedent will not receive a "step up" in tax basis of such Securities to fair market value.

Special rules also apply to the amount of foreign tax credit that a U.S. Holder may claim on a distribution from a PFIC. Subject to such special rules, foreign taxes paid with respect to any distribution in respect of stock in a PFIC are generally eligible for the foreign tax credit. The rules relating to distributions by a PFIC and their eligibility for the foreign tax credit are complicated, and a U.S. Holder should consult with their own tax advisor regarding the availability of the foreign tax credit with respect to distributions by a PFIC.

The PFIC rules are complex, and each U.S. Holder should consult its own tax advisor regarding the PFIC rules (including the applicability and advisability of a QEF Election and Mark-to-Market Election) and how the PFIC rules may affect the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Securities.

U.S. Federal Income Tax Consequences of the Exercise and Disposition of Common Warrants

The following discussion describes the general rules applicable to the ownership and disposition of the Common Warrants but is subject in its entirety to the special rules described above under the heading “Passive Foreign Investment Company Rules.”

Exercise of Common Warrants

A U.S. Holder should not recognize gain or loss on the exercise of a Common Warrant and related receipt of a Common Warrant Share (unless cash is received in lieu of the issuance of a fractional Common Warrant Share). A U.S. Holder’s initial tax basis in the Common Warrant Share received on the exercise of a Common Warrant should be equal to the sum of (a) such U.S. Holder’s tax basis in such Common Warrant plus (b) the exercise price paid by such U.S. Holder on the exercise of such Common Warrant. If, as anticipated, the Company is a PFIC, a U.S. Holder’s holding period for the Common Warrant Share will begin on the date on which such U.S. Holder acquired its Common Warrants.

In certain limited circumstances, a U.S. Holder may be permitted to undertake a cashless exercise of Common Warrants into Common Warrant Shares. The U.S. federal income tax treatment of a cashless exercise of Common Warrants into Common Warrant Shares is unclear, and the tax consequences of a cashless exercise could differ from the consequences upon the exercise of a Common Warrant described in the preceding paragraph. U.S. Holders should consult their own tax advisors regarding the U.S. federal income tax consequences of a cashless exercise of Common Warrants.

Disposition of Common Warrants

A U.S. Holder will recognize gain or loss on the sale or other taxable disposition of a Common Warrant in an amount equal to the difference, if any, between (a) the amount of cash plus the fair market value of any property received and (b) such U.S. Holder’s tax basis in the Common Warrant sold or otherwise disposed of. Subject to the PFIC rules discussed above, any such gain or loss generally will be a capital gain or loss, which will be long-term capital gain or loss if the Common Warrant is held for more than one year. Deductions for capital losses are subject to complex limitations under the Code.

Expiration of Common Warrants Without Exercise

Upon the lapse or expiration of a Common Warrant, a U.S. Holder will recognize a loss in an amount equal to such U.S. Holder’s tax basis in the Common Warrant. Any such loss generally will be a capital loss and will be long-term capital loss if the Common Warrants are held for more than one year. Deductions for capital losses are subject to complex limitations under the Code.

Certain Adjustments to the Common Warrants

Under Section 305 of the Code, an adjustment to the number of Common Warrant Shares that will be issued on the exercise of the Common Warrants, or an adjustment to the exercise price of the Common Warrants, may be treated as a constructive distribution to a U.S. Holder of the Common Warrants if, and to the extent that, such adjustment has the effect of increasing such U.S. Holder’s proportionate interest in the “earnings and profits” or the Company’s assets, depending on the circumstances of such adjustment (for example, if such adjustment is to compensate for a distribution of cash or other property to the shareholders). Adjustments to the exercise price of Common Warrants made pursuant to a bona fide reasonable adjustment formula that has the effect of preventing dilution of the interest of the holders of the Common Warrants should generally not be considered to result in a constructive distribution. Any such constructive distribution would be taxable whether or not there is an actual distribution of cash or other property. (See more detailed discussion of the rules applicable to distributions made by the Company at “Distributions on Common Shares, Pre-Funded Warrants and Warrant Shares” below).

General Rules Applicable to U.S. Federal Income Tax Consequences of the Acquisition, Ownership, and Disposition of Common Shares, Pre-Funded Warrants and Warrant Shares

The following discussion describes the general rules applicable to the ownership and disposition of the Common Shares, Pre-Funded Warrants and Warrant Shares but is subject in its entirety to the special rules described above under the heading “Passive Foreign Investment Company Rules.”

Distributions on Common Shares, Pre-Funded Warrants and Warrant Shares

A U.S. Holder that receives a distribution, including a constructive distribution, with respect to a Common Share, Pre-Funded Warrants or Warrant Share (as well as any constructive distribution on a Warrant as described above) will be required to include the amount of such distribution in gross income as a dividend (without reduction for any Canadian income tax withheld from such distribution) to the extent of our current and accumulated “earnings and profits”, as computed under U.S. federal income tax principles. A dividend generally will be taxed to a U.S. Holder at ordinary income tax rates the Company is a PFIC for the tax year of such distribution or the preceding tax year. To the extent that a distribution exceeds the current and accumulated “earnings and profits” of the Company, such distribution will be treated first as a tax-free return of capital to the extent of a U.S. Holder’s tax basis in the Common Shares, Pre-Funded Warrants or Warrant Shares and thereafter as gain from the sale or exchange of such Common Shares, Pre-Funded Warrants or Warrant Shares (see “Sale or Other Taxable Disposition of Common Shares, Pre-Funded Warrants and/or Warrant Shares” below). However, the Company may not maintain the calculations of earnings and profits in accordance with U.S. federal income tax principles, and each U.S. Holder may be required to assume that any distribution by the Company with respect to the Common Shares, Pre-Funded Warrants or Warrant Shares will constitute ordinary dividend income. Dividends received on Common Shares, Pre-Funded Warrants or Warrant Shares generally will not be eligible for the “dividends received deduction” generally applicable to corporations. Subject to applicable limitations and provided the Company is eligible for the benefits of the Convention Between Canada and the United States of America with Respect to Taxes on Income and on Capital, signed September 26, 1980, as amended, or the Common Shares are readily tradable on a United States securities market, dividends paid by the Company to non-corporate U.S. Holders, including individuals, generally will be eligible for the preferential tax rates applicable to long-term capital gains for dividends, provided certain holding period and other conditions are satisfied, including that the Company not be classified as a PFIC in the tax year of distribution or in the preceding tax year. The dividend rules are complex, and each U.S. Holder should consult its own tax advisor regarding the application of such rules.

Sale or Other Taxable Disposition of Common Shares, Pre-Funded Warrants and/or Warrant Shares

Upon the sale or other taxable disposition of Common Shares, Pre-Funded Warrants or Warrant Shares, a U.S. Holder generally will recognize capital gain or loss in an amount equal to the difference between (a) the amount of cash plus the fair market value of any property received and (b) such U.S. Holder’s tax basis in such Common Shares, Pre-Funded Warrants or Warrant Shares sold or otherwise disposed of. Gain or loss recognized on such sale or other taxable disposition generally will be long-term capital gain or loss if, at the time of the sale or other taxable disposition, the Common Shares, Pre-Funded Warrants or Warrant Shares have been held for more than one year. Preferential tax rates may apply to long-term capital gain of a U.S. Holder that is an individual, estate, or trust. There are no preferential tax rates for long-term capital gain of a U.S. Holder that is a corporation. Deductions for capital losses are subject to significant limitations under the Code.

Additional Tax Considerations

Receipt of Foreign Currency

The amount of any distribution paid to a U.S. Holder in foreign currency or on the sale, exchange or other taxable disposition of Common Shares, Pre-Funded Warrants, Common Warrants or Warrant Shares generally will be equal to the U.S. dollar value of such foreign currency based on the exchange rate applicable on the date of receipt (regardless of whether such foreign currency is converted into U.S. dollars at that time). If the foreign currency received is not converted into U.S. dollars on the date of receipt, a U.S. Holder will have a tax basis in the foreign currency equal to its U.S. dollar value on the date of receipt. Any U.S. Holder who receives payment in foreign currency and engages in a subsequent conversion or other disposition of the foreign currency may have a foreign currency exchange gain or loss that would be treated as ordinary income or loss, and generally will be U.S. source income or loss for foreign tax credit purposes. Different rules apply to U.S. Holders who use the accrual method of tax accounting. Each U.S. Holder should consult its own U.S. tax advisor regarding the U.S. federal income tax consequences of receiving, owning, and disposing of foreign currency.

Foreign Tax Credit

Subject to the PFIC rules discussed above, a U.S. Holder that pays (whether directly or through withholding) Canadian income tax with respect to dividends paid on the Common Shares, Pre-Funded Warrants or Warrant Shares (or with respect to any constructive dividend on the Common Warrants) generally will be entitled, at the election of such U.S. Holder, to receive either a deduction or a credit for such Canadian income tax paid. Generally, a credit will reduce a U.S. Holder's U.S. federal income tax liability on a dollar-for-dollar basis, whereas a deduction will reduce a U.S. Holder's income subject to U.S. federal income tax. This election is made on a year-by-year basis and applies to all foreign taxes paid or accrued (whether directly or through withholding) by a U.S. Holder during a year. The foreign tax credit rules are complex and involve the application of rules that depend on a U.S. Holder's particular circumstances. Accordingly, each U.S. Holder should consult its own tax advisor regarding the foreign tax credit rules.

Information Reporting: Backup Withholding Tax

Under U.S. federal income tax laws certain categories of U.S. Holders must file information returns with respect to their investment in, or involvement in, a foreign corporation. For example, U.S. return disclosure obligations (and related penalties) are imposed on U.S. Holders that hold certain specified foreign financial assets in excess of certain threshold amounts. The definition of specified foreign financial assets includes not only financial accounts maintained in foreign financial institutions, but also, unless held in accounts maintained by a financial institution, any stock or security issued by a non-U.S. person. U.S. Holders may be subject to these reporting requirements unless their Securities are held in an account at certain financial institutions. Penalties for failure to file certain of these information returns are substantial. U.S. Holders should consult their own tax advisors regarding the requirements of filing information returns, including the requirement to file IRS Form 8938.

Payments made within the U.S., or by a U.S. payor or U.S. middleman, of dividends on, and proceeds arising from the sale or other taxable disposition of the Securities generally may be subject to information reporting and backup withholding tax, currently at the rate of 24%, if a U.S. Holder (a) fails to furnish its correct U.S. taxpayer identification number (generally on Form W-9), (b) furnishes an incorrect U.S. taxpayer identification number, (c) is notified by the IRS that such U.S. Holder has previously failed to properly report items subject to backup withholding tax, or (d) fails to certify, under penalty of perjury, that it has furnished its correct U.S. taxpayer identification number and that the IRS has not notified such U.S. Holder that it is subject to backup withholding tax. However, certain exempt persons, such as U.S. Holders that are corporations, generally are excluded from these information reporting and backup withholding tax rules. Any amounts withheld under the U.S. backup withholding tax rules will be allowed as a credit against a U.S. Holder's U.S. federal income tax liability, if any, or will be refunded, if such U.S. Holder furnishes required information to the IRS in a timely manner.

The discussion of reporting requirements set forth above is not intended to constitute a complete description of all reporting requirements that may apply to a U.S. Holder. A failure to satisfy certain reporting requirements may result in an extension of the time period during which the IRS can assess a tax and, under certain circumstances, such an extension may apply to assessments of amounts unrelated to any unsatisfied reporting requirement. Each U.S. Holder should consult its own tax advisors regarding the information reporting and backup withholding rules.

THE ABOVE SUMMARY IS NOT INTENDED TO CONSTITUTE A COMPLETE ANALYSIS OF ALL TAX CONSIDERATIONS APPLICABLE TO U.S. HOLDERS WITH RESPECT TO THE ACQUISITION, OWNERSHIP, AND DISPOSITION OF SECURITIES. U.S. HOLDERS SHOULD CONSULT THEIR OWN TAX ADVISORS AS TO THE TAX CONSIDERATIONS APPLICABLE TO THEM IN THEIR OWN PARTICULAR CIRCUMSTANCES.

PLAN OF DISTRIBUTION

We have engaged H.C. Wainwright & Co., LLC, to act as our exclusive placement agent in connection with this Offering of our Securities pursuant to this Prospectus Supplement and the Registration Statement. Under the terms of the engagement agreement, the Placement Agent has agreed to be our exclusive placement agent, on a reasonable best-efforts basis, in connection with the issuance and sale by us of the securities in this takedown from our shelf Registration Statement. The terms of this Offering were subject to market conditions and negotiations between us, the Placement Agent and the investors. The engagement agreement does not give rise to any commitment by the Placement Agent to purchase any of our Securities, and the Placement Agent will have no authority to bind us by virtue of the engagement agreement. Further, the Placement Agent does not guarantee that it will be able to raise new capital in any prospective offering. The Placement Agent may engage sub-agents or selected dealers to assist with the Offering.

The Placement Agent proposes to arrange for the sale of the Securities we are offering pursuant to this Prospectus Supplement and the Registration Statement to one or more investors through a securities purchase agreement directly between the investors and us. We will only sell to investors who have entered into the securities purchase agreement. We expect to deliver the Securities being offered pursuant to this Prospectus Supplement on or about June 10, 2020, subject to satisfaction of certain customary closing conditions.

Fees and Expenses

We have agreed to pay the Placement Agent a total cash fee equal to 7.0% of the gross proceeds of this Offering. We will also pay the Placement Agent up to \$75,000 for all reasonable, out-of-pocket expenses incurred by the Placement Agent (including fees and expenses of legal counsel) in connection with the matters contemplated by our agreement with the Placement Agent, as well as \$12,900 for clearing fees.

We estimate the total expenses payable by us for this Offering will be approximately \$1.6 million, which amount includes the Placement Agent fees and expenses.

Placement Agent Warrants

We have agreed to issue to Wainwright the Placement Agent Warrants to purchase up to 1,260,000 Shares, representing 7.0% of the aggregate number of Common Shares and Pre-Funded Warrants sold in this Offering. The Placement Agent Warrants will have an exercise price equal to \$1.25, or 125% of the offering price per Common Share and one-half Common Warrant combination and will be exercisable for 4 years from the date of the closing of this Offering. Pursuant to FINRA Rule 5110(g), the Placement Agent Warrants and any Shares issued upon exercise of the Placement Agent Warrants shall not be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of the securities by any person for a period of 180 days immediately following the date of effectiveness or commencement of sales of this Offering, except the transfer of any security: (i) by operation of law or by reason of our reorganization; (ii) to any FINRA member firm participating in the Offering and the officers or partners thereof; (iii) if the aggregate amount of our securities held by the Placement Agent or related persons do not exceed 1% of the securities being offered; (iv) that is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member manages or otherwise directs investments by the fund and the participating members in the aggregate do not own more than 10% of the equity in the fund; or (v) the exercise or conversion of any security.

Indemnification

We have agreed to indemnify the Placement Agent and specified other persons against certain liabilities relating to or arising out of the Placement Agent's activities under the engagement agreement and to contribute to payments that the Placement Agent may be required to make in respect of such liabilities.

Regulation M

The Placement Agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received by it and any profit realized on the resale of the securities sold by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. As an underwriter, the Placement Agent would be required to comply with the requirements of the Securities Act and the Exchange Act, including, without limitation, Rule 415(a)(4) under the Securities Act and Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of Common Shares and warrants by the Placement Agent acting as principal. Under these rules and regulations, the Placement Agent:

- may not engage in any stabilization activity in connection with our securities; and
- may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until it has completed its participation in the distribution.

Other Relationships

The Placement Agent and its respective affiliates have engaged in, and may in the future engage in, investment banking and other commercial dealings in the ordinary course of business with us or our affiliates. The Placement Agent has received, or may in the future receive, customary fees and commissions for these transactions.

Listing

Our Common Shares are listed on the TSX under the symbol “TMD” and the Nasdaq under the symbol “TMDI”.

DILUTION

If you invest in our Common Shares, you will experience dilution to the extent of the difference between the price per Common Share you pay in the Offering and the net tangible book value per share of our Common Share immediately after the Offering. As of March 31, 2020, we had a negative net tangible book value of approximately \$(10,036,702) or \$(0.19) per Common Share, based upon 54,216,877 Common Shares outstanding on such date. Net tangible book value per Share represents the amount of our total tangible assets reduced by the amount of our total liabilities and divided by the total number of Common Shares outstanding.

Dilution in net tangible book value per Share to new investors in the Offering represents the difference between the amount per Share paid by purchasers in the Offering and the net tangible book value per Common Share immediately after the completion of the Offering. After giving effect to the sale of the Common Shares offered by us hereby, as set forth on the cover page of this Prospectus Supplement, and after deducting the Placement Agent fees and commissions and estimated Offering expenses payable by us, in the amount of \$1.6 million, but not giving effect to (i) any exercise of 9,000,000 Common Warrants and 1,260,000 Placement Agent Warrants, (ii) estimated non-cash costs of the warrants issued to the Placement Agent, (iii) any exercise of outstanding stock options, (iv) any exercise of outstanding broker warrants and (v) any exercise of outstanding warrants, (vi) the issuance of Common Shares issued to investors as part of our offering that closed on May 6, 2020, and (vii) the issuance of Common Shares on exercise of warrants since March 31, 2020, our net tangible book value as of March 31, 2020, after giving effect to the above, would have been \$(6,362,148) or \$(0.09) per Common Share. This represents an immediate increase in net tangible book value of \$0.28 per share to existing stockholders and an immediate decrease of \$(0.91) per share to new investors in our Common Shares.

New investors will experience further dilution if any of our outstanding stock options are exercised or new stock options are issued and exercised under our equity incentive plan. Additionally, we may choose to raise additional capital through the sale of equity or other securities based on market conditions or strategic considerations. To the end, that we raise additional capital in this manner, the issuance of such securities could result in further dilution to stockholders.

EXPENSES OF ISSUANCE AND DISTRIBUTION

The following is a statement of the expenses (all of which are estimated), other than any underwriting discounts and commissions and expenses reimbursed by us, if any, to be incurred in connection with the Offering.

Legal fees and expenses	\$	150,000
Accountants' fees and expenses		18,000
Transfer agent fees and expenses		65,000
Miscellaneous		3,100
Total	\$	<u>236,100</u>

LEGAL MATTERS

Certain legal matters relating to the Offering under this Prospectus Supplement are being passed upon for Titan in Canada by Borden Ladner Gervais LLP, Toronto, Ontario, Titan's Canadian counsel, and in the United States by Dorsey & Whitney LLP, Titan's U.S. counsel, and on behalf of the Placement Agent by Ellenoff Grossman & Schole LLP, New York, New York.

EXPERTS

The financial statements incorporated in this Prospectus Supplement by reference to the Company's Annual Report on Form 20-F dated March 30, 2020 have been incorporated in reliance on the report of BDO Canada LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.

PROSPECTUS

TITAN MEDICAL INC.

Common Shares

Units

Warrants to Purchase Common Shares

\$125,000,000

Titan Medical Inc. (the “**Company**,” “**Titan**,” “**we**,” “**us**” or “**our**”) may offer and issue from time to time (the “**Offering**”) common shares (“**Common Shares**” or “**Shares**”) of our company, warrants to purchase Shares (“**Warrants**”) and units consisting of Shares and whole or partial Warrants (“**Units**”, and together with the Common Shares and the Warrants, the “**Securities**”) or any combination thereof for up to an aggregate initial offering price of \$125,000,000 (or the equivalent thereof in other currencies) during the 36 month period that this registration statement (the “**Prospectus**”), including any amendments hereto, remains effective. Securities will be offered for cash, and may be offered separately or together, in amounts, at prices and on terms to be determined based on market conditions at the time of sale as set forth in an accompanying prospectus supplement (a “**Prospectus Supplement**”).

The specific terms of the Securities with respect to a particular Offering will be set out in the applicable Prospectus Supplement and may include, where applicable (i) in the case of Shares, the number of Shares offered, the offering price, and any other terms specific to the Shares being offered, (ii) in the case of Warrants, the offering price, the designation, the number and the terms of the Shares purchasable upon exercise of the Warrants, any procedures that will result in the adjustment of these numbers, the exercise price, the dates and periods of exercise and any other terms specific to the Warrants being offered, and (iii) in the case of Units, the number of Units offered, the offering price of the Units, the number, designation and terms of the Shares and Warrants comprising the Units and any procedures that will result in the adjustment of those numbers and any other specific terms applicable to the offering of Units. Where required by statute, regulation or policy, and where Securities are offered in currencies other than United States dollars, appropriate disclosure of foreign exchange rates applicable to the Securities will be included in the Prospectus Supplement describing the Securities.

All shelf information permitted under applicable law to be omitted from this Prospectus will be contained in one or more Prospectus Supplements that will be delivered to purchasers together with this Prospectus. Each Prospectus Supplement will be incorporated by reference into this Prospectus for the purposes of securities legislation as of the date of the Prospectus Supplement and only for the purposes of the distribution of the Securities to which the Prospectus Supplement pertains.

This Prospectus constitutes a public offering of the Securities only in those jurisdictions where they may be lawfully offered for sale and only by persons permitted to sell the Securities in those jurisdictions. We may offer and sell Securities to, or through, underwriters or dealers and also may offer and sell certain Securities directly to other purchasers or through agents pursuant to exemptions from registration or qualification under applicable securities laws. A Prospectus Supplement relating to each issue of Securities offered thereby will set forth the names of any underwriters, dealers, or agents involved in the Offering and sale of the Securities and will set forth the terms of the Offering of the Securities, the method of distribution of the Securities including, to the extent applicable, the proceeds we will receive and any fees, discounts or any other compensation payable to underwriters, dealers or agents and any other material terms of the plan of distribution.

The outstanding Common Shares are listed on the Toronto Stock Exchange (the “**TSX**”) under the symbol “TMD” and the NASDAQ (the “**Nasdaq**”) under the symbol “TMDI”. On July 29, 2019 (the last trading day prior to the date of this Prospectus), the closing price of the Common Shares on: (i) the TSX was CAD \$2.85; and (ii) the Nasdaq was \$2.15. We will apply to have any Common Shares distributed under this Prospectus listed on the TSX and the Nasdaq provided the Common Shares are currently listed or traded on such exchanges. Any listing and admission will be subject to Titan fulfilling all of the listing requirements of the TSX and the Nasdaq, respectively. Unless otherwise specified in the applicable Prospectus Supplement, no Securities, other than Common Shares, will be listed or admitted to trading on any securities exchange.

Our principal executive offices are located at 170 University Avenue, Suite 1000, Toronto, Ontario, Canada, M5H 3B3 (telephone [1-416-548-7522](tel:1-416-548-7522)).

We have prepared this Prospectus in accordance with United States disclosure requirements. Our financial statements are prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”) and thus may not be comparable to financial statements of United States companies.

Purchasers of the Securities should be aware that the acquisition of the Securities may have tax consequences in the United States and in Canada. Such consequences for purchasers who are resident in, or citizens of, the United States, or who are resident in Canada may not be described fully herein or in any applicable Prospectus Supplement. Purchasers of the Securities should read the tax discussion contained in the applicable Prospectus Supplement with respect to a particular Offering of Securities.

The enforcement by investors of civil liabilities under United States federal securities laws may be affected adversely by the fact that Titan is incorporated and governed under the laws of the Province of Ontario, Canada, that a number of our officers and directors are residents of countries other than the United States, that some or all of the underwriters, if any, may be residents of a foreign country, and a substantial portion of our assets and some of said persons are located outside the United States.

No underwriter has been involved in the preparation of this Prospectus nor has any underwriter performed any review of the contents of this Prospectus.

Investing in the Securities involves a high degree of risk. Prospective purchasers of the Securities should carefully consider all the information in this Prospectus and in the documents incorporated by reference in this Prospectus. See “Risk Factors” beginning on page 10 of this Prospectus.

The date of this Prospectus is August 2, 2019.

TABLE OF CONTENTS**Page**

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION	6
PUBLICALLY AVAILABLE INFORMATION ON TITAN	8
DOCUMENTS INCORPORATED BY REFERENCE	9
RISK FACTORS	10
MATERIAL CHANGES	10
CONSOLIDATED CAPITALIZATION	11
DESCRIPTION OF SHARE CAPITAL	11
MEMORANDUM AND ARTICLES OF ASSOCIATION	14
USE OF PROCEEDS	22
PLAN OF DISTRIBUTION	23
DESCRIPTION OF SECURITIES	24
TRADING	25
DILUTION	25
EXPENSES OF ISSUANCE AND DISTRIBUTION	26
DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES	26
MATERIAL CONTRACTS	26
EXCHANGE CONTROLS	26
CERTAIN INCOME TAX CONSIDERATIONS	27
DOCUMENTS ON DISPLAY	27
EXPERTS	27
LEGAL MATTERS	27
INTEREST OF EXPERTS AND COUNSEL	27

You should rely only on the information contained in or incorporated by reference into this Prospectus or any Prospectus Supplement. References to this “Prospectus” include documents incorporated by reference therein. See “Documents Incorporated by Reference”. The information in or incorporated by reference into this Prospectus is current only as of its date. We have not authorized anyone to provide you with information that is different. This document may only be used where it is legal to offer these Securities.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

Forward-looking Statements

This Prospectus, including the documents incorporated by reference herein, contains forward-looking statements and forward-looking information (collectively, “**forward-looking statements**”) within the meaning of United States securities laws relating to us that are based on the beliefs and estimates of our management as well as assumptions made by and information currently available to us. Such forward-looking statements include, but are not limited to statements concerning:

- our technology and research and development objectives, including development milestones, and achieving design freeze, estimated costs, schedules for completion and probability of success;
- our intention with respect to updating any forward-looking statement after the date on which such statement is made or to reflect the occurrence of unanticipated events;
- expectation with respect to planned acute and chronic animal studies and human cadaver studies to be conducted under Good Laboratory Practices and anticipation of filing and Investigational Device Exemption (“**IDE**”) with the U.S. Food and Drug Administration (“**FDA**”);
- the Company’s expectation that the FDA will grant IDE approval and that the Company will then proceed to collect suitable confirmatory human data to support its 510(k) application to the FDA, and Technical File for the CE Mark;
- expectation that it can in a timely manner produce the appropriate preclinical and clinical data required for its 510(k) application to the FDA, and Technical File for the CE Mark;
- our expectation with respect to launching a commercial product in certain jurisdictions
- our intentions to develop a robust training curriculum and post-training assessment tools
- our plans to develop and commercialize our single-port robotic surgical system and the estimated incremental costs (including the status, cost and timing of achieving the development milestones disclosed herein);
- our plans to design, create and refine software for production system functionality of our single-port robotic surgical system and the estimated incremental costs (including the status, cost and timing of achieving the development milestones disclosed herein);
- our intentions to complete formative and summative human factors studies
- our intentions with respect to initiating marketing activities following receipt of the applicable regulatory approvals
- our expectation for the surgical indications for, and the benefits of, our single-port robotic surgical system
- our intention to continue to assess specialized skill and knowledge requirements and the recruitment of qualified personnel and partners;

- our belief that the specialized components, parts and know-how necessary for the manufacture of the single-port robotic surgical system, suitable for clinical use, will be available in the marketplace;
- our belief that existing and planned systems will be suitable to support human factors studies, animal and human cadaver studies, human confirmatory studies, and 2019 activities related to filing its applications for regulatory clearance;
- our intention of filing and prosecution of patent applications to expand the Company's intellectual property portfolio as technologies are developed or refined;
- our seeking of licensing opportunities to expand our intellectual property portfolio;
- our intended use of proceeds of any offering of our securities;
- our intention with respect to not paying any cash dividends on Common Shares in the foreseeable future;
- our intention to retain future earnings, if any, to finance expansion and growth;
- projected competitive conditions with respect to our products;
- the estimated size of the market for robotic surgical systems for abdominal surgery, and
- the potential market for the securities issuable under the Offering.

When used in this Prospectus, any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, assumptions or future events of performance (often but not always using words or phrases such as "anticipate", "believe", "estimate", "expect", "intend", "plan", "strategy", "goals", "objectives", "project", "potential" or variations thereof or stating that certain actions, events, or results "may", "could", "would", "might" or "will" be taken, occur, or be achieved, or the negative of any of these terms and similar expressions), as they relate to us or our management, are intended to identify forward-looking statements.

Such forward-looking statements reflect our current views with respect to future events and are subject to certain known and unknown risks, uncertainties and assumptions. Many factors could cause actual results, performance, or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others:

- risks relating to our ability to obtain additional financing;
- risks relating to our history of losses;
- risks and uncertainties relating to the generating sustainable earnings from our contemplated products;
- risks related to loss of key members of management and/or ability to attract and retain qualified employees;
- risks related to dependence on third parties retained to conduct preclinical studies;
- risks related to increased competition in the robotic surgical market;
- risks related to licensing and/or infringement of intellectual property rights of third parties;
- risks related to the price and volume volatility of the Common Shares;

- risks related to governmental regulations and approval processes of Food and Drug Administration of the United States Department of Health and Human Services, including possible changes thereto;
- risks related to acceptance of our technology; and
- risks related to the ability to maintain the listing of the Common Shares on the TSX and Nasdaq.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein. This list is not exhaustive of the factors that may affect any of our forward-looking statements. Forward-looking statements are statements about the future and are inherently uncertain, and our actual achievements or other future events or conditions may differ materially from those reflected in the forward-looking statements due to a variety of risks, uncertainties and other factors, including without limitation, those referred to in this document under the heading “Risk Factors”, in our 40-F and the Annual Information Form (each as defined below) and elsewhere. The forward-looking statements in this Prospectus are based on the reasonable beliefs, expectations and opinions of management on the date the forward-looking statements are made, and, except as required by law, we do not assume any obligation to update forward-looking statements if circumstances or our management’s beliefs, expectations or opinions should change.

For the reasons set forth above, investors should not attribute undue certainty to or place undue reliance on forward-looking statements.

Additional risks and uncertainties relating to us and our business can be found in the “Risk Factors” section of this Prospectus and in any applicable Prospectus Supplement, as well as in our other documents incorporated by reference herein.

PUBLICALLY AVAILABLE INFORMATION ON TITAN

We file reports and other information with the securities commissions and similar regulatory authorities in the provinces of Canada (collectively, the “Commissions”). These reports and information are available to the public free of charge on SEDAR at www.sedar.com.

We are subject to the information requirements of the U.S. Securities Exchange Act of 1934, as amended (the “U.S. Exchange Act”), relating to foreign private issuers and applicable Canadian securities legislation and, in accordance therewith, file reports and other information with the SEC and securities regulatory authorities in Canada. As a foreign private issuer, we are exempt from the rules under the U.S. Exchange Act prescribing the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the U.S. Exchange Act.

Investors may read any document that we have filed with the SEC at the SEC’s public reference room in Washington, D.C. Investors may also obtain copies of those documents from the public reference room of the SEC at 100 F Street, N.E., Washington, D.C. 20549 by paying a fee. Investors should call the SEC at 1-800-SEC-0330 or access its website at www.sec.gov for further information about the public reference rooms. Investors may also read and download documents we have filed with the SEC’s Electronic Data Gathering and Retrieval system at www.sec.gov.

Readers should rely only on information contained or incorporated by reference in this Prospectus and any applicable Prospectus Supplement. We have not authorized anyone to provide the reader with different information. We are not making an offer of the Securities in any jurisdiction where the offer is not permitted. Readers should not assume that the information contained in this Prospectus is accurate as of any date other than the date on the front of this Prospectus, unless otherwise noted herein or as required by law. It should be assumed that the information appearing in this Prospectus and the documents incorporated herein by reference are accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed since those dates.

DOCUMENTS INCORPORATED BY REFERENCE

Information has been incorporated by reference in this Prospectus from documents filed with the Commissions and filed with, or furnished to, the SEC Copies of the documents incorporated herein by reference may be obtained on request without charge upon written or oral request from our Chief Financial Officer at 170 University Avenue, Suite 1000, Toronto, Ontario, Canada, M5H 3B3 (telephone 416-548-7522). Copies of these documents are also available through the Internet on the System for Electronic Document Analysis and Retrieval, which can be accessed online at www.sedar.com and on the SEC's Electronic Data Gathering and Retrieval System, which can be accessed online at www.sec.gov and at our website at www.titanmedicalinc.com

The following documents, which we filed or furnished with the Commissions and the SEC, as applicable, are specifically incorporated by reference into, and form an integral part of, this Prospectus:

- (a) Our Form 40-F Annual Report dated March 29, 2019 for the year ended December 31, 2018 (the "**40-F**") filed with the SEC on March 29, 2019;
- (b) Our Material Change Report dated March 6, 2019 which was included as Exhibit 99.1 to the Form 6-K filed with the SEC on March 8, 2019;
- (c) Our Material Change Report dated March 28, 2019 which was included as Exhibit 99.4 to the Form 6-K filed with the SEC on May 31, 2019;
- (d) Our Unaudited Condensed Interim Financial Statements for the three-month period ended March 31, 2019, which were included as Exhibit 99.2 to the Form 6-K filed with the SEC on May 15, 2019;
- (e) Our Management Discussion and Analysis for the three-month period ended March 31, 2019 (the "**March 2019 MD&A**"), which was included as Exhibit 99.3 to the Form 6-K filed with the SEC on May 15, 2019;
- (f) Our management information circular for the annual general meeting of shareholders held on May 29, 2019 which was included as Exhibit 99.6 to the Form 6-K filed with the SEC on May 31, 2019; and

In addition, this Prospectus shall also be deemed to incorporate by reference all subsequent annual reports filed on Form 20-F, Form 40-F or Form 10-K, and all subsequent filings on Forms 10-Q and 8-K filed by us pursuant to the U.S. Exchange Act prior to the termination of the Offering made by this Prospectus. We may incorporate by reference into this Prospectus any Form 6-K that is submitted to the SEC after the date of the filing of the registration statement of which this Prospectus forms a part and before the date of termination of this Offering. Any such Form 6-K that we intend to so incorporate shall state in such form that it is being incorporated by reference into this Prospectus. The documents incorporated or deemed to be incorporated herein by reference contain meaningful and material information relating to us and the readers should review all information contained in this Prospectus and the documents incorporated or deemed to be incorporated herein by reference.

A Prospectus Supplement containing the specific terms of an Offering of Securities and other information relating to the Securities will be delivered to prospective purchasers of such Securities together with this Prospectus and will be deemed to be incorporated into this Prospectus as of the date of such Prospectus Supplement only for the purpose of the Offering of the Securities covered by that Prospectus Supplement.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Prospectus, to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not constitute a part of this Prospectus, except as so modified or superseded. The modifying or superseding statement need not state that it has modified or superseded a prior statement or include any other information set forth in the document that it modifies or supersedes. The making of such a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation, an untrue statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary to make a statement not misleading in light of the circumstances in which it was made.

RISK FACTORS

An investment in our Securities is highly speculative and subject to a number of known and unknown risks. Only those persons who can bear the risk of the entire loss of their investment should purchase our Securities. You should carefully consider the risk factors set forth below along with the risk factors in the 40-F, the March 2019 MD&A and the other information contained in this Prospectus, as updated by our subsequent filings under the U.S. Exchange Act, and the risk factors and other information contained in any applicable Prospectus Supplement, before purchasing any of our Securities.

You may experience future dilution as a result of future equity offerings.

In order to raise additional capital, we may in the future offer additional Common Shares or other securities convertible into or exchangeable for Common Shares at prices that may not be the same as the price per share paid by any investor in an offering in a subsequent Prospectus Supplement. We may sell shares or other securities in any other offering at a price per share that is less than the price per share or other security paid by any investor in an offering in a subsequent Prospectus Supplement, and investors purchasing shares or other securities in the future could have rights superior to you. The price per share at which we sell additional Common Shares or securities convertible or exchangeable into Common Shares, in future transactions may be higher or lower than the price per share paid by any investor in an offering under a subsequent Prospectus Supplement.

There can be no assurance as to the liquidity of the trading market for certain Securities or that a trading market for certain Securities will develop.

With the exception of certain warrants previously issued by us and listed on the TSX, there is no public market for our warrants, unless otherwise specified in the applicable Prospectus Supplement, the Company does not intend to apply for listing of Warrants. If these securities are traded after their initial issue, they may trade at a discount from their initial offering prices depending on the market for similar securities, prevailing interest rates and other factors, including general economic conditions and the Company's financial condition. There can be no assurance as to the liquidity of the trading market for any Warrants or that a trading market for these securities will develop.

There will be no market for the Units.

We have not applied and do not intend to apply to list the Units on any securities exchange. There will be no market through which Units may be sold and purchasers may not be able to resell Units purchased in any Offering. If the Units are traded after their initial issue, they may trade at a discount from their initial offering prices depending on the market conditions, prevailing interest rates and other factors, including general economic conditions and our financial condition. There can be no assurance as to the liquidity of the trading market for the Units or that a trading market for such Units will develop.

MATERIAL CHANGES

Except as otherwise disclosed in this Prospectus there have been no material changes to our operations that have occurred since December 31, 2018, and that have not been described in a report on Form 6-K furnished under the U.S. Exchange Act and incorporated by reference into this Prospectus.

CONSOLIDATED CAPITALIZATION

The following table sets forth our capitalization and indebtedness as of March 31, 2019. This table should be read in conjunction with our unaudited interim condensed consolidated financial statements as at and for the three months ended March 31, 2019, which are incorporated by reference into this Prospectus.

	As at March 31, 2019
Liabilities	
Accounts payable and accrued liabilities	\$ 6,495,644
Other current liabilities – with warrant liability	33,774,970
Total current liabilities	40,270,614
Loan payable	0
Long-term liability	0
Total non-current liabilities	0
Equity	
Common shares	189,726,067
Warrants	0
Contributed surplus	6,903,766
Deficit	(201,220,574)
Total equity/(deficit)	(4,590,741)
Total liabilities and equity	35,679,873

There have been no material changes in our share capital, on a consolidated basis, since the date of our unaudited interim condensed consolidated financial statements as at and for the three month period ended March 31, 2019, which are incorporated by reference in the Prospectus.

DESCRIPTION OF SHARE CAPITAL

Common Shares

Our authorized share capital consists of an unlimited number of Common Shares with no par value of which 31,150,237 were issued and outstanding as at March 31, 2019.

The holders of Common Shares are entitled to receive notice of and to attend all annual and special meetings of our shareholders and to one vote in respect of each Common Share held at the record date for each such meeting. The holders of Common Shares are entitled, at the discretion of the Board, to receive out of any or all of our profits or surplus properly available for the payment of dividends, any dividend declared by the Board and payable by us on the Common Shares. The holders of the Common Shares will participate *pro rata* in any distribution of our assets upon liquidation, dissolution or winding-up or other distribution of our assets. Such participation will be subject to the rights, privileges, restrictions and conditions attached to any of our securities issued and outstanding at such time ranking in priority to the Common Shares upon our liquidation, dissolution or winding-up. Common Shares are issued, on authorization and approval from the Board, from treasury without par value and only as fully paid and are non-assessable. Common Shares will only be issued through the book-based system administered by CDS in Canada and by DTC in the United States, except in limited circumstances.

Warrants

As of the date of this prospectus, we have 21,203,411 warrants outstanding to purchase Common Shares at exercise prices ranging from \$3.20 to \$36.07. The holders of Warrants are entitled to exercise, prior to expiry of the Warrant, a Warrant to purchase an equal number of Common Shares upon delivery to the Company of the aggregate price specified in the Warrant for receiving a Common Share. Only on receipt of a Common Share, and not prior, is a person entitled to the rights that holders of Common Shares (as outlined above) are entitled to.

All outstanding warrants are governed by warrant indentures entered into between the Company and Computershare Trust Company of Canada (or its predecessor, Olympia Transfer Services Inc.), as warrant agent thereunder, and/or warrant certificates, as the case may be, dated the date of issue of each series of warrants.

Share Options

The Company has established a stock option plan for officers, directors, employees and service providers of the Company, prepared in compliance with the requirements of the TSX, which is administered by the Board. As of the date of this Prospectus, we have 960,195 Common Share options outstanding with an exercise price that ranges between 1.55 and 43.28.

Share Capital History

On June 19, 2018, a share consolidation, on the basis of 30 pre-consolidation Common Shares forming one post-consolidation Common Share, was completed and our outstanding common shares were adjusted from 419,888,250 to 13,996,275. The number of Common Shares purchasable upon the exercise of each warrant, broker warrant and stock option has been adjusted one to 0.033333 (requiring 30 warrants, 30 broker warrants or 30 options, as the case may be, to purchase one Common Share). Where appropriate, all references to units, Common Shares, warrants, and stock options have been updated to reflect the 1:30 share consolidation.

Issuances During Q1 2019

In addition, we completed an offering of securities pursuant to an agency agreement dated March 18, 2019 between the Company and Bloom Burton Securities Inc. (“**Bloom Burton**”). We sold 8,455,882 units under the offering at a price of \$3.40 per unit for gross proceeds of approximately \$28,750,000. Each unit consisted of one Common Share of the Company and one Common Share purchase warrant, each warrant entitling the holder to acquire one Common Share at an exercise price of \$4.00 and expiring March 21, 2024. We issued broker warrants to Bloom Burton entitling the holder to purchase 591,911 Common Shares at a price of \$3.40 and expiring March 18, 2021.

In addition, we issued 1,018,506 Common Shares upon the exercise of Common Share purchase warrants at an exercise price of \$3.20.

Issuances During Q3 2018

On August 10, 2018, we completed an offering of securities pursuant to an agency agreement dated August 7, 2018 between the Company and Bloom Burton. We sold 7,679,574 units under the offering at a price of \$2.50 per unit for gross proceeds of approximately \$19,198,935. Each unit consisted of one Common Share and one Common Share purchase warrant, each warrant entitling the holder to acquire one Common Share at an exercise price of \$3.20 and expiring August 10, 2023. In connection with the offering, 537,570 broker warrants were issued each entitling the holder to acquire one Common Share at a price of \$2.50 and expiring August 10, 2020.

Issuances During Q2 2018

On April 10, 2018, we completed an offering of securities pursuant to an agency agreement dated April 3, 2018 between Bloom Burton and us. We sold 1,126,665 units under the Offering at a price of CAD \$9.00 per unit for gross proceeds of approximately \$8,035,941. Each unit consisted of one Common Share and 0.03333 warrant, each whole warrant entitling the holder to acquire one Common Share at an exercise price of CAD \$10.50 and expiring April 10, 2023. In connection with the offering, 89,795 broker warrants were issued entitling the holder to acquire one Common Share at a price of CAD \$9.00 and expiring April 10, 2020.

On May 10, 2018, we announced the exercise of the over-allotment option granted to Bloom Burton as agent for our offering, at a price of CAD \$9.00 per unit, completed on April 10, 2018 wherein we sold an additional 168,889 units at the offering price for additional gross proceeds of \$1,189,856. Each unit consisted of one Common Share and 0.03333 warrant, each whole warrant entitling the holder to acquire one Common Share at an exercise price of CAN \$10.50 and expiring April 10, 2023.

Issuances During Q1 2018

We issued an aggregate of 6,497 Common Shares upon the exercise of Common Share purchase warrants at exercise prices between CAD \$6.00 and CAD \$8.10. We also issued an aggregate of 7,500 Common Shares pursuant to consultant agreements at a prices between CAD \$8.10 and CAD \$12.60.

Issuances During Q4 2017

On December 5, 2017, we completed an offering of units made pursuant to an agency agreement dated November 30, 2017 between Bloom Burton and us. We sold 1,533,333 units at a price of CAD \$15.00 per unit for gross proceeds of approximately \$18,137,800. Each unit consisted of one Common Share and 0.03333 warrant, each whole warrant entitling the holder to acquire one additional Common Share at an exercise price of CAD \$18.00 and expiring December 5, 2022. In connection with the offering, 105,350 broker warrants were issued entitling the holder to acquire one Common Share at a price of CAD \$15.00 and expiring December 5, 2019. On October 20, 2017 and October 30, 2017, we completed a non-brokered private placement offering of 446,197 Common Shares, for aggregate gross proceeds of \$2,677,326, to subscribers in Canada, the United States and Europe.

We issued an aggregate of 1,404,753 Common Shares upon the exercise of Common Share purchase warrants and broker warrants at exercise prices between CAD \$4.50 and CAD \$15.00. We also issued an aggregate of 7,500 Common Shares pursuant to consultant agreements at a prices between CAD \$11.40 and CAD \$14.40.

Issuances During Q2 and Q3 2017

On June 29, 2017, we completed an offering of securities pursuant to an agency agreement dated June 26, 2017 between Bloom Burton and us. At the first closing on June 29, 2017, we sold 1,612,955 units at a price of CAD \$4.50 per unit for gross proceeds of approximately \$5,576,357. Each unit consisted of one Common Share and 0.03333 warrant, each whole warrant entitling the holder to acquire one Common Share at an exercise price of CAD \$6.00 and expiring June 29, 2022. On July 21, 2017, Titan completed the second closing of the offering pursuant to which we sold an additional 370,567 units at a price of CAD \$4.50 per unit for gross proceeds of approximately \$1,328,871. In connection with the offering, 135,473 broker warrants were issued entitling the holder to acquire one Common Share at a price of CAD \$4.50 and expiring June 29, 2019.

Additionally, on August 24, 2017, we completed a \$2,000,000 equity conversion with Longtai Medical Inc. ("**Longtai Medical**"), pursuant to which 563,067 units were issued. Each unit consisted of one Common Share and 0.03333 warrant, each whole warrant entitling Longtai Medical to acquire one additional Common Share at an exercise price of CAD \$6.00 and expiring August 24, 2022.

We issued an aggregate of 525,585 Common Shares upon the exercise of Common Share purchase warrants at exercise prices between CAD \$6.00 and CAD \$12.00.

Issuances During Q1 2017

On March 16, 2017, Titan completed an offering of securities made pursuant to an agency agreement dated March 10, 2017 between Bloom Burton and us. We sold 715,573 units under the offering at a price of CAD \$10.50 per unit for gross proceeds of approximately \$5,642,537. Each unit consisted of one Common Share and (i) 0.01666 of one warrant, each whole warrant entitling the holder to acquire one Common Share at an exercise price of CAD \$12.00 and expiring March 16, 2019, and (ii) 0.01666 of one warrant, each whole warrant entitling the holder to acquire one Common Share at an exercise price of CAD \$15.00 and expiring March 16, 2021. In connection with the offering, 50,005 broker warrants were issued entitling the holder to acquire one Common Share at a price of CAD \$10.50, which expired on March 16, 2019.

Issuances During H2 2016

On September 20, 2016, we completed an offering of securities pursuant to an agency agreement dated September 13, 2016 between us and Bloom Burton and Echelon Wealth Partners Inc. We sold 569,444 units under the offering at a price of CAD \$18.00 per unit for gross proceeds of \$7,749,000. Each unit consisted of one Common Share and 0.03333 warrant, each whole warrant entitling the holder to acquire one Common Share at an exercise price of CAD \$22.50 and expiring September 20, 2021. On October 27, 2016, the Company sold an additional 67,667 units at the offering price of CAD \$18.00 per unit for additional gross proceed of \$909,846 pursuant to the exercise of the over-allotment option. In connection with the offering, 38,850 broker warrants were issued entitling the holder to acquire one Common Share at a price of CAD \$22.50, which expired on September 20, 2018.

MEMORANDUM AND ARTICLES OF ASSOCIATION

Incorporation

We are an Ontario corporation, being the successor corporation formed pursuant to an amalgamation under the *Business Corporations Act* (Ontario) (the "OBCA") on July 28, 2008.

Objects and Purposes of the Company

Our articles do not contain and are not required to contain a description of our objects and purposes. There is no restriction contained in our articles on the business that we may carry on.

Voting on Certain Proposal, Arrangement, Contract or Compensation by Directors

Other than as disclosed below, neither our articles nor our corporate by-laws restrict our directors' power to (a) vote on a proposal, arrangement or contract in which the directors are materially interested or (b) to vote with regard to compensation payable to themselves or any other members of their body in the absence of an independent quorum.

Our corporate by-laws provide that a director or officer who: (a) is a party to; or (b) is a director or an officer of, or has a material interest in, any person who is a party to; a material contract or transaction or proposed material contract or transaction with us shall disclose the nature and extent of such director's or officer's interest at the time and in the manner provided by the OBCA. Any such contract or transaction or proposed material contract or transaction shall be referred to our Board or shareholders for approval in accordance with the OBCA even if such contract or proposed material contract or transaction is one that in the ordinary course of our business would not require approval by our Board or shareholders, and a director interested in a contract or transaction so referred to our Board shall not attend any part of a meeting of our Board during which the contract or transaction is discussed and shall not vote on any resolution to approve such contract or transaction except as provided by the OBCA.

Subject to our articles and any unanimous shareholder agreement, our directors shall be paid such remuneration for their services as our Board may from time to time determine. Our directors shall also be entitled to be reimbursed for travelling and other expenses properly incurred by them in attending meetings of our Board or any committee thereof.

The OBCA provides that a director who holds a disclosable interest in a contract or transaction into which we have entered or propose to enter shall not attend any part of a meeting of directors during which the contract or transaction is discussed and shall not vote on any resolution to approve the contract or transaction unless it is a contract or transaction: (i) relating primarily to such director's remuneration as a director of the company or one of our affiliates; (ii) for indemnity or insurance for the benefit of such director in his/her capacity as a director; or (iii) with one of our affiliates.

A director or officer who holds a disclosable interest in a contract or transaction into which we have entered or propose to enter is not accountable to us or our shareholders for any profit or gain realized from the contract or transaction and the contract or transaction is neither void nor voidable by reason only of that relationship or by reason only that the director is present at or is counted to determine the presence of a quorum at the meeting of directors that authorized the contract or transaction, if the director or officer disclosed his or her interest in accordance with the OBCA and the contract or transaction was reasonable and fair to us at the time it was approved.

The OBCA provides that a director or officer generally holds a disclosable interest in a contract or transaction if either (a) the director or officer is a party to the contract or transaction with us or a proposed contract or transaction with us, and such contract or transaction is material to us; or (b) the director or officer is a director or an officer of, or has a material interest in, any person who is a party to a material contract or transaction or proposed material contract or transaction with us.

Borrowing Powers of Directors

Our articles and corporate by-laws provide that, if authorized by our directors, we may:

- borrow money upon our credit;
- issue sell or pledge debt obligations (including bonds, debentures, notes or other similar obligations, secured or unsecured) of the Company; and
- charge, mortgage, hypothecate, pledge all or any of the currently owned or subsequently acquired real or personal, movable or immovable, property of the Company, including book debts, rights, powers, franchises and undertakings, to secure any debt obligations or money borrowed, or other debt or liability of the Company.

Amendment to the borrowing powers described above requires an amendment to our articles and corporate by-laws. Our articles and corporate by-laws do not contain any provisions in connection with amending the by-laws. The OBCA provides that our Board may by resolution, make, amend or repeal any by-laws that regulate our business and affairs and that our Board will submit such by-law, amendment or repeal to our shareholders at the next meeting of shareholders and the shareholders may, by ordinary resolution, confirm, reject or amend the by-law, amendment or repeal.

Qualifications of Directors

Under our articles and corporate by-laws, a director is not required to hold a share in our capital as qualification for his or her office but must be qualified as required by the OBCA to become, act or continue to act as a director. The OBCA provides that the following persons are disqualified from being a director of a corporation: (i) a person who is less than 18 years of age; (ii) a person who has been found under the *Substitute Decisions Act, 1992* or under the *Mental Health Act* to be incapable of managing property or who has been found to be incapable by a court in Canada or elsewhere; (iii) a person who is not an individual; and (iv) a person who has the status of a bankrupt.

Subject to the OBCA, at least 25% of the directors must be resident Canadians. If we have less than four directors, at least one director must be a resident Canadian.

Share Rights

See the discussion in the section of this prospectus entitled "Description of Share Capital" for a summary of our authorized capital and the rights attached to our common shares.

Procedures to Change the Rights of Shareholders

The rights, privileges, restrictions and conditions attaching to our shares are contained in our articles and such rights, privileges, restrictions and conditions may be changed by amending our articles. In order to amend our articles, the OBCA requires a resolution to be passed by a majority of not less than two-thirds of the votes cast by the shareholders entitled to vote thereon. In addition, if we resolve to make particular types of amendments to our articles, a holder of our shares may dissent with regard to such resolution and, if such shareholder so elects, we would have to pay such shareholder the fair value of the shares held by the shareholder in respect of which the shareholder dissents as of the close of business on the day before the resolution was adopted. The types of amendments that would be subject to dissent rights include without limitation: (i) to add, remove or change restrictions on the issue, transfer or ownership of shares of a class or series of our shares; and (ii) to add, remove or change any restriction upon the business that we may carry on or upon the powers that we may exercise.

Meetings

Each director holds office until our next annual general meeting or until his office is earlier vacated in accordance with our articles or with the provisions of the OBCA. A director appointed or elected to fill a vacancy on our board also holds office until our next annual general meeting.

Annual meetings of our shareholders must be held at such time in each year not more than 15 months after the last annual meeting, as our Board may determine. Notice of the time and place of a meeting of shareholders must be sent not less than twenty-one days and not more than fifty days, before the meeting.

Meetings of our shareholders shall be held at our registered office or, if our Board shall so determine, at some other place in Ontario or, at some place outside Ontario if all the shareholders entitled to vote at the meeting so agree.

Our Board, the chair of our Board or our chief executive officer shall have power to call a special meeting of our shareholders at any time.

The OBCA provides that our shareholders may requisition a special meeting in accordance with the OBCA. The OBCA provides that the holders of not less than five percent of our issued shares that carry the right to vote at a meeting may requisition our directors to call a special meeting of shareholders for the purposes stated in the requisition.

Under our by-laws, the quorum for the transaction of business at a meeting of our shareholders is one person, present in person or by proxy and holding in aggregate not less than 20% of our issued shares entitled to vote at such meeting.

Limitations on Ownership of Securities

There is no limitation imposed by the laws of Canada or by the Company's constating documents on the right of a non-resident to hold or vote the Common Shares, other than as provided in the *Investment Canada Act*. The following discussion summarizes the principal features of the *Investment Canada Act* for a non-resident who proposes to acquire the Common Shares.

The *Investment Canada Act* requires each "non-Canadian" (as defined in the *Investment Canada Act*) who acquires "control" of an existing "Canadian business", where the acquisition of control is not a reviewable transaction, to file a notification in prescribed form with the responsible federal government department or departments not later than 30 days after closing. Subject to certain exemptions, a transaction that is reviewable under the *Investment Canada Act* may not be implemented until an application for review has been filed and the responsible Minister of the federal cabinet has determined that the investment is likely to be of "net benefit to Canada" taking into account certain factors set out in the *Investment Canada Act*.

Under the *Investment Canada Act*, an investment in the Company's Common Shares by a non-Canadian who is a World Trade Organization member country investor that is not a state-owned enterprise, would be reviewable only if it were an investment to acquire control of the Company pursuant to the *Investment Canada Act* and the enterprise value of the Company's assets (as determined pursuant to the *Investment Canada Act* and its regulations) was equal to or greater than CAD \$1.045 billion, or CAD \$1.568 billion in the case of a "trade agreement investor". The *Investment Canada Act* contains various rules to determine if there has been an acquisition of control. For example, for purposes of determining whether an investor has acquired control of a corporation by acquiring shares, the following general rules apply, subject to certain exceptions: the acquisition of a majority of the undivided ownership interests in the voting shares of the corporation is deemed to be an acquisition of control of that corporation; the acquisition of less than a majority, but one-third or more, of the voting shares of a corporation or of an equivalent undivided ownership interest in the voting shares of the corporation is presumed to be an acquisition of control of that corporation unless it can be established that, on the acquisition, the corporation is not controlled in fact by the acquirer through the ownership of voting shares; and the acquisition of less than one third of the voting shares of a corporation or of an equivalent undivided ownership interest in the voting shares of the corporation is deemed not to be an acquisition of control of that corporation.

Under the *Investment Canada Act*, a national security review on a discretionary basis may also be undertaken by the federal government with respect to any investment by a non-Canadian to "acquire, in whole or part, or to establish an entity carrying on all or any part of its operations in Canada." No financial threshold applies to a national security review. The relevant test is whether the investment by a non-Canadian could be "injurious to national security." Review on national security grounds may occur on a pre- or post-closing basis.

Certain transactions relating to the Company's Common Shares will generally be exempt from the *Investment Canada Act*, subject to the federal government's prerogative to conduct a national security review, including:

- (1) the acquisition of the Company's Common Shares by a person in the ordinary course of that person's business as a trader or dealer in securities;
- (2) the acquisition of control of the Company in connection with the realization of security granted for a loan or other financial assistance and not for any purpose related to the provisions of the *Investment Canada Act*, and
- (3) the acquisition of control of the Company by reason of an amalgamation, merger, consolidation or corporate reorganization following which the ultimate direct or indirect control in fact of the Company, through ownership of the Company's Common Shares, remains unchanged.

Change in Control

There are no provisions in our articles or by-laws that would have the effect of delaying, deferring or preventing a change in control of the Company, and that would operate only with respect to a merger, acquisition or corporate restructuring involving the Company or our subsidiaries.

Ownership Threshold

Neither our by-laws nor our articles contain any provisions governing the ownership threshold above which shareholder ownership must be disclosed. In addition, securities legislation in Canada requires that we disclose in our proxy information circular for our annual meeting and certain other disclosure documents filed by us under such legislation, holders who beneficially own more than 10% of our issued and outstanding shares.

Differences in Corporate Law

We are governed by the OBCA, which is generally similar to laws applicable to United States corporations. Significant differences between the OBCA and the Delaware General Corporate Law, or DGCL, which governs companies incorporated in the State of Delaware, include the following:

Board of Director Quorum and Vote Requirements

Delaware

Under the DGCL, a majority of the total number of directors shall constitute a quorum for the transaction of business unless the certificate or bylaws require a greater number. The bylaws may lower the number required for a quorum to one-third the number of directors, but no less.

Under the DGCL, the board of directors may take action by the majority vote of the directors present at a meeting at which a quorum is present unless the certificate of incorporation or bylaws require a greater vote.

Ontario

Under the OBCA, subject to an Ontario corporation's articles or bylaws, a majority of the number of directors or minimum number of directors required by the articles constitutes a quorum at any meeting of directors. Where a corporation has fewer than three directors, all directors must be present at any meeting to constitute a quorum.

Under the OBCA, subject to an Ontario corporation's articles or bylaws, where there is a vacancy or vacancies in the board of directors, the remaining directors may exercise all the powers of the board so long as a quorum of the board remains in office.

Transactions with Directors and Officers

Delaware

The DGCL generally provides that no transaction between a corporation and one or more of its directors or officers, or between a corporation and any other corporation or other organization in which one or more of its directors or officers, are directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the board or committee which authorizes the transaction, or solely because any such director's or officer's votes are counted for such purpose, if (i) the material facts as to the director's or officer's interest and as to the transaction are known to the board of directors or the committee, and the board or committee in good faith authorizes the transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum (ii) the material facts as to the director's or officer's interest and as to the transaction are disclosed or are known to the stockholders entitled to vote thereon, and the transaction is specifically approved in good faith by vote of the stockholders; or (iii) the transaction is fair as to the Company as of the time it is authorized, approved or ratified, by the board of directors, a committee or the stockholders.

Ontario

The OBCA requires that a director or officer of a corporation who is: (i) a party to a material contract or transaction or proposed material contract or transaction with the Company; or (ii) a director or an officer of, or has a material interest in, any person who is a party to a material contract to or transaction or proposed material contract or transaction with the Company shall disclose in writing to the Company or request to have entered in the minutes of meetings of directors the nature and extent of his or her interest. An interested director is prohibited from attending the part of the meeting during which the contract or transaction is discussed and is prohibited from voting on a resolution to approve the contract or transaction except in specific circumstances, such as a contract or transaction relating primarily to his or her remuneration as a director, a contract or transaction for indemnification or liability insurance of the director, or a contract or transaction with an affiliate of the Company. If a director or officer has disclosed his or her interest in accordance with the OBCA and the contract or transaction was reasonable and fair to the Company at the time it was approved, the director or officer is not accountable to the Company or its shareholders for any profit or gain realized from the contract or transaction and the contract or transaction is neither void nor voidable by reason only of the interest of the director or officer or that the director is present at or is counted to determine the presence of a quorum at the meeting of directors that authorized the contract or transaction.

The OBCA further provides that even if a director or officer does not disclose his or her interest in accordance with the OBCA, or (in the case of a director) votes in respect of a resolution on a contract or transaction in which he or she is interested contrary to the OBCA, if the director or officer acted honestly and in good faith and the contract or transaction was reasonable and fair to the Company at the time it was approved, the director or officer is not accountable to the Company or to its shareholders for any profit or gain realized from the contract or transaction by reason only of his or her holding the office of the director or officer and the contract or transaction is not by reason only of the director's or officer's interest therein void or voidable, if the contract or transaction has been confirmed or approved by the shareholders by special resolution, on the basis of disclosure in reasonable detail of the nature and extent of the director's or officer's interest in the notice of meeting or management information circular.

Call and Notice of Stockholder Meetings

Delaware

Under the DGCL, an annual or special stockholder meeting is held on such date, at such time and at such place as may be designated by the board of directors or any other person authorized to call such meeting under the Company's certificate of incorporation or bylaws. If an annual meeting for election of directors is not held on the date designated or an action by written consent to elect directors in lieu of an annual meeting has not been taken within 30 days after the date designated for the annual meeting, or if no date has been designated, for a period of 13 months after the later of the last annual meeting or the last action by written consent to elect directors in lieu of an annual meeting, the Delaware Court of Chancery may summarily order a meeting to be held upon the application of any stockholder or director.

Stockholder Action by Written Consent

Delaware

Under the DGCL, a majority of the stockholders of a corporation may act by written consent without a meeting unless such action is prohibited by the Company's certificate of incorporation.

Stockholder Nominations and Proposals

Delaware

Not applicable.

Ontario

Under the OBCA, the directors of a corporation are required to call an annual meeting of shareholders no later than fifteen months after holding the last preceding annual meeting. Under the OBCA, the directors of a corporation may call a special meeting at any time. In addition, holders of not less than five percent of the issued shares of a corporation that carry the right to vote at a meeting sought to be held may requisition the directors to call a meeting of shareholders.

Ontario

Under the OBCA, a written resolution signed by all the shareholders of a corporation who would have been entitled to vote on the resolution at a meeting is effective to approve the resolution.

Ontario

Under the OBCA, a shareholder entitled to vote at a shareholders' meeting may submit a shareholder proposal relating to matters which the shareholder wishes to propose and discuss at a shareholders' meeting and, subject to such shareholder's compliance with the prescribed time periods and other requirements of the OBCA pertaining to shareholder proposals, the Company is required to include such proposal in the information circular pertaining to any meeting at which it solicits proxies, subject to certain exceptions. Notice of such a proposal must be provided to the Company at least 60 days before the anniversary date of the last annual shareholders' meeting, or at least 60 days before any other meeting at which the matter is proposed to be raised.

In addition, the OBCA requires that any shareholder proposal that includes nominations for the election of directors must be signed by one or more holders of shares representing in the aggregate not less than five per cent of the shares or five per cent of the shares of a class or series of shares of the Company entitled to vote at the meeting to which the proposal is to be presented.

Stockholder Quorum and Vote Requirements

Delaware

Under the DGCL, quorum for a stock corporation is a majority of the shares entitled to vote at the meeting unless the certificate of incorporation or bylaws specify a different quorum, but in no event may a quorum be less than one-third of the shares entitled to vote. Unless the DGCL, certificate of incorporation or bylaws provide for a greater vote, generally the required vote under the DGCL is a majority of the shares present in person or represented by proxy, except for the election of directors which requires a plurality of the votes cast.

Amendment of Governing Instrument

Delaware

Amendment of Certificate of Incorporation. Generally, under the DGCL, the affirmative vote of the holders of a majority of the outstanding stock entitled to vote is required to approve a proposed amendment to the certificate of incorporation, following the adoption of the amendment by the board of directors of the Company, provided that the certificate of incorporation may provide for a greater vote. Under the DGCL, holders of outstanding shares of a class or series are entitled to vote separately on an amendment to the certificate of incorporation if the amendment would have certain consequences, including changes that adversely affect the rights and preferences of such class or series.

Amendment of Bylaws. Under the DGCL, after a corporation has received any payment for any of its stock, the power to adopt, amend or repeal bylaws shall be vested in the stockholders entitled to vote; provided, however, that any corporation may, in its certificate of incorporation, provide that bylaws may be adopted, amended or repealed by the board of directors. The fact that such power has been conferred upon the board of directors shall not divest the stockholders of the power nor limit their power to adopt, amend or repeal the bylaws.

Votes on Mergers, Consolidations and Sales of Assets

Delaware

The DGCL provides that, unless otherwise provided in the certificate of incorporation or bylaws, the adoption of a merger agreement requires the approval of a majority of the outstanding stock of the Company entitled to vote thereon.

Ontario

Under the OBCA, unless the bylaws otherwise provide, the holders of a majority of the shares of an OBCA corporation entitled to vote at a meeting of shareholders, whether present in person or represented by proxy, constitute a quorum.

Ontario

Amendment of Articles. Under the OBCA, amendments to the articles of incorporation generally require the approval of not less than two-thirds of the votes cast by shareholders entitled to vote on the resolution.

Amendment of Bylaws. Under the OBCA, the directors may, by resolution, make, amend or repeal any bylaws that regulate the business or affairs of a corporation and they must submit the bylaw, amendment or repeal to the shareholders at the next meeting of shareholders, and the shareholders may confirm, reject or amend the bylaw, amendment or repeal.

Ontario

Under the OBCA, the approval of at least two-thirds of votes cast by shareholders entitled to vote on the resolution is required for extraordinary corporate actions. Extraordinary corporate actions include: amalgamations; continuances; sales, leases or exchanges of all or substantially all of the property of a corporation; liquidations and dissolutions.

Dissenter's Rights of Appraisal

Delaware

Under the DGCL, a stockholder of a Delaware corporation generally has the right to dissent from a merger or consolidation in which the Delaware corporation is participating, subject to specified procedural requirements, including that such dissenting stockholder does not vote in favor of the merger or consolidation. However, the DGCL does not confer appraisal rights, in certain circumstances, including if the dissenting stockholder owns shares traded on a national securities exchange and will receive publicly traded shares in the merger or consolidation. Under the DGCL, a stockholder asserting appraisal rights does not receive any payment for his or her shares until the court determines the fair value or the parties otherwise agree to a value. The costs of the proceeding may be determined by the court and assessed against the parties as the court deems equitable under the circumstances.

Change of Control Restrictions

Delaware

Unless an issuer opts out of the provisions of Section 203 of the DGCL, Section 203 generally prohibits a public Delaware corporation from engaging in a "business combination" with a holder of 15% or more of the Company's voting stock (as defined in Section 203), referred to as an interested stockholder, for a period of three years after the date of the transaction in which the interested stockholder became an interested stockholder, except as otherwise provided in Section 203. For these purposes, the term "business combination" includes mergers, assets sales and other similar transactions with an interested stockholder.

Ontario

Under the OBCA each of the following matters listed will entitle shareholders to exercise rights of dissent and to be paid the fair value of their shares: (i) any amalgamation with another corporation (other than with certain affiliated corporations); (ii) an amendment to the Company's articles to add, change or remove any provisions restricting the issue, transfer or ownership of that class of shares; (iii) an amendment to the Company's articles to add, change or remove any restriction upon the business or businesses that the Company may carry on; (iv) a continuance under the laws of another jurisdiction; (v) a sale, lease or exchange of all or substantially all the property of the Company other than in the ordinary course of business; and (vi) where a court order permits a shareholder to dissent in connection with an application to the court for an order approving an arrangement.

However, a shareholder is not entitled to dissent if an amendment to the articles is effected by a court order approving a reorganization or by a court order made in connection with an action for an oppression remedy, unless otherwise authorized by the court. The OBCA provides these dissent rights for both listed and unlisted shares.

Under the OBCA, a shareholder may, in addition to exercising dissent rights, seek an oppression remedy for any act or omission of a corporation which is oppressive or unfairly prejudicial to or that unfairly disregards a shareholder's interests.

Ontario

While the OBCA does not contain specific anti-takeover provisions with respect to "business combinations", rules and policies of certain Canadian securities regulatory authorities, including Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101"), contain requirements in connection with, among other things, "related party transactions" and "business combinations", including, among other things, any transaction by which an issuer directly or indirectly engages in the following with a related party: acquires, sells, leases or transfers an asset, acquires the related party, acquires or issues treasury securities, amends the terms of a security if the security is owned by the related party or assumes or becomes subject to a liability or takes certain other actions with respect to debt.

The term “related party” includes directors, senior officers and holders of more than 10% of the voting rights attached to all outstanding voting securities of the issuer or holders of a sufficient number of any securities of the issuer to materially affect control of the issuer.

MI 61-101 requires, subject to certain exceptions, the preparation of a formal valuation relating to certain aspects of the transaction and more detailed disclosure in the proxy material sent to security holders in connection with a related party transaction including related to the valuation. MI 61-101 also requires, subject to certain exceptions, that an issuer not engage in a related party transaction unless the shareholders of the issuer, other than the related parties, approve the transaction by a simple majority of the votes cast.

USE OF PROCEEDS

Unless otherwise specified in a Prospectus Supplement, the net proceeds from the sale of the Securities will be used to continue developing our single-port robotic surgical system, to prepare our regulatory filings in anticipation of commercialization and for general corporate purposes, including funding working capital, potential future acquisitions and capital expenditures.

We anticipate the successful completion of prerequisite live animal and human cadaver studies early in the third quarter of 2019, and plan to file our IDE application with the FDA by the end of the third quarter of 2019. Although timing of our IDE application approval by the FDA, and Institutional Review Board approvals by each IDE hospital site, cannot be precisely known, we continue to target the filing of a 510(k) application with the FDA by year end 2019.

As a result of this timeline, over the course of the next two quarters, ending September 30 and December 31, 2019, we approximate our cash needs to be \$25.7 million and \$16.6 million respectively. We estimate that this capital will be sufficient for us to fund our operations through to December 31, 2019, which is the target date for filing our 510(k) application with the FDA.

Anticipated Use of Funding for Third Quarter of 2019

During the third quarter of 2019, we expect to use \$25.7 million to complete the following milestones:

- Complete and document preclinical live animal (swine) and cadaver studies according to final protocols for FDA submittal;
- Submit IDE application to FDA;
- Obtain ISO 13485 Certification; and
- Receive IDE approval from FDA.

Anticipated Use of Funding for Fourth Quarter of 2019

During the fourth quarter of 2019, we expect to use \$16.6 million to complete the following milestones:

- Complete and document human confirmatory studies under IDE protocol for FDA submittal;

- Submit Technical File to European Notified Body for CE Mark; and
- Submit 510(k) application to FDA.

Anticipated Use of Funding for the Year 2020

We expect that, given the complexity of our robotic surgical system and the approval process for similar systems, it could take approximately six months to receive final 510(k) clearance from the FDA. During the first and second quarters of 2020, our investment in research and development will diminish significantly as we transition to manufacturing and approach commercialization. We approximate our cash requirements to be \$6.1 and \$3.3 million respectively in the first and second quarters of 2020. These funds will be used in connection with preparation for manufacturing and commercialization of our robotic surgical system.

Following receipt of FDA 510(k) clearance, which we project to occur during the third quarter of 2020, we plan to commence commercialization, with initial revenue anticipated to begin during the third or fourth quarter of 2020.

Each Prospectus Supplement will contain further specific information concerning the use of proceeds from the sale of Securities covered in such Prospectus Supplement, and may modify and supersede the expected use of proceeds disclosed in this Prospectus to the extent subsequently required in light of the timeline for achievement of the milestones indicated above. All expenses relating to an Offering of Securities and any compensation paid to underwriters, dealers or agents, as the case may be, will be paid out of our general funds, unless otherwise stated in the applicable Prospectus Supplement.

PLAN OF DISTRIBUTION

We may sell the Securities, separately or together, to or through underwriters or dealers purchasing as principals for public offering and sale by them, and also may sell Securities to one or more other purchasers directly or through agents. Each Prospectus Supplement will set forth the terms of the Offering, including the name or names of any underwriters or agents, if any, the purchase price or prices of the Securities and the proceeds we will receive from the sale of the Securities.

The Securities may be sold from time to time in one or more transactions at a fixed price or prices which may be changed or at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices including sales in transactions that are deemed to be “at-the-market” distributions, including sales made directly on the TSX, Nasdaq or other existing trading markets for the securities. The prices at which the Securities may be offered may vary as between purchasers and during the period of distribution. If, in connection with the Offering of Securities at a fixed price or prices, the underwriters, if any, have made a bona fide effort to sell all of the Securities at the initial offering price fixed in the applicable Prospectus Supplement, the public offering price may be decreased and thereafter further changed, from time to time, to an amount not greater than the initial public offering price fixed in such Prospectus Supplement, in which case the compensation realized by the underwriters will be decreased by the amount that the aggregate price paid by purchasers for the Securities is less than the gross proceeds paid to us by the underwriters.

Underwriters, dealers and agents who participate in the distribution of the Securities may be entitled under agreements to be entered into with us to indemnification by us against certain liabilities, including liabilities under the Securities Act of 1933 and Canadian securities legislation, or to contribution with respect to payments which such underwriters, dealers or agents may be required to make in respect thereof. Such underwriters, dealers and agents may be customers of, engage in transactions with, or perform services for, us in the ordinary course of business.

In connection with any Offering of Securities, except as otherwise set out in a Prospectus Supplement relating to a particular Offering of Securities, the underwriters may over-allot or effect transactions intended to maintain or stabilize the market price of the Securities offered at a level above that which might otherwise prevail in the open market. Such transactions, if commenced, may be discontinued at any time.

DESCRIPTION OF SECURITIES

Common Shares

We may issue Common Shares. Shares may be offered separately or together with other Securities and may be attached to or separate from any other Securities. See “Description of Share Capital” for a description of the general terms that will apply to any Shares issued pursuant to this Prospectus. The Shares to be issued in connection with any Offering hereunder will be authorized by our Board at such time as the Board determines to conduct an Offering hereunder.

Warrants

We may issue Warrants to purchase Shares. This section describes the general terms that will apply to any Warrants issued pursuant to this Prospectus. Warrants may be offered separately or together with other Securities and may be attached to or separate from any other Securities.

Each series of Warrants may be issued under a separate warrant indenture to be entered into between us and one or more banks or trust companies acting as Warrant agent. The Warrant agent will act solely as our agent and will not assume a relationship of agency with any holders of Warrant certificates or beneficial owners of Warrants.

The applicable Prospectus Supplement will include details of the warrant indentures, if any, governing the Warrants being offered. The specific terms of the Warrants, and the extent to which the general terms described in this section apply to those Warrants, will be set out in the applicable Prospectus Supplement. The Prospectus Supplement relating to any Warrants we offer will describe the Warrants and the specific terms relating to the Offering. The description will include, where applicable:

- the designation and aggregate number of Warrants;
- the price at which the Warrants will be offered;
- the currency or currencies in which the Warrants will be offered;
- the date on which the right to exercise the Warrants will commence and the date on which the right will expire;
- the designation, number and terms of the Shares that may be purchased upon exercise of the Warrants, and the procedures that will result in the adjustment of those numbers;
- the exercise price of the Warrants and any provisions for changes or adjustments in the exercise price;
- the designation and terms of the Securities, if any, with which the Warrants will be offered, and the number of Warrants that will be offered with each Security;
- if the Warrants are issued as a Unit with another Security, the date, if any, on and after which the Warrants and the other Security will be separately transferable;
- any minimum or maximum amount of Warrants that may be exercised at any one time;
- any terms, procedures and limitations relating to the transferability, exchange or exercise of the Warrants;

- whether the Warrants will be subject to redemption or call and, if so, the terms of such redemption or call provisions;
- as applicable, material United States and Canadian federal income tax consequences of owning the Warrants; and
- any other material terms or conditions of the Warrants.

Warrant certificates will be exchangeable for new Warrant certificates of different denominations at the office indicated in the Prospectus Supplement. Prior to the exercise of their Warrants, holders of Warrants will not have any of the rights of holders of Shares. We may amend the warrant indenture(s), if any, and the Warrants, without the consent of the holders of the Warrants, to cure any ambiguity, to cure, correct or supplement any defective or inconsistent provision, or in any other manner that will not prejudice the rights of the holders of outstanding Warrants, as a group.

We have not applied and do not intend to apply to list the Warrants on any securities exchange. There will be no market through which the Warrants may be sold and purchasers may not be able to resell the Warrants purchased in the Offering. This may affect the pricing of the Warrants in the secondary market, the transparency and availability of trading prices, the liquidity of the Warrants, and the extent of issuer regulation.

Units

We may issue Units, which may consist of one or more Shares, Warrants or any combination of Securities as is specified in the relevant Prospectus Supplement. In addition, the relevant Prospectus Supplement relating to an Offering of Units will describe all material terms of any Units offered, including, as applicable:

- the designation and aggregate number of Units being offered;
- the price at which the Units will be offered;
- the designation, number and terms of the Securities comprising the Units and any agreement governing the Units;
- the date or dates, if any, on or after which the Securities comprising the Units will be transferable separately;
- whether we will apply to list the Units on any exchange;
- material income tax consequences of owning the Units, including how the purchase price paid for the Units will be allocated among the Securities comprising the Units; and
- any other material terms or conditions of the Units.

TRADING

The Common Shares are listed for trading in Canada on the TSX under the symbol "TMD". The Common Shares are also traded on the Nasdaq in the United States under the symbol "TMDI".

DILUTION

Purchasers of Securities in an Offering may suffer immediate and substantial dilution in the net tangible book value per share of Common Shares. Dilution in net tangible book value per share represents the difference between the amount per Share paid by purchasers in an Offering and the net tangible book value per share of Common Shares immediately after an Offering.

EXPENSES OF ISSUANCE AND DISTRIBUTION

The following is a statement of the expenses (all of which are estimated), other than any underwriting discounts and commissions and expenses reimbursed by us, if any, to be incurred in connection with a distribution of an assumed amount of \$125,000,000 of Securities under the Offering.

SEC registration fees	\$	15,150
Nasdaq Listing fees		(1)
TSX Listing fees		(1)
Printing Expenses		(1)
Legal fees and expenses		(1)
Accountants' fees and expenses		(1)
Transfer agent fees and expenses		(1)
Miscellaneous		(1)
Total	\$	<u>15,150</u>

Notes:

(1) To be provided by a Prospectus Supplement, or as an exhibit to a Report on Form 6-K that is incorporated by reference into this Prospectus.

DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

MATERIAL CONTRACTS

There are no material contracts to which we are a party other than contracts entered into in the ordinary course of business.

EXCHANGE CONTROLS

There are no governmental laws, decrees, regulations or other legislation, including foreign exchange controls, in Canada which may affect the export or import of capital or that may affect the remittance of dividends, interest or other payments to non-resident holders of the Company's securities. Any remittances of dividends to United States residents, however, are subject to a withholding tax pursuant to the Income Tax Act (Canada) and the Canada-U.S. Income Tax Convention (1980), each as amended. Remittances of interest to U.S. residents entitled to the benefits of such Convention are generally not subject to withholding taxes except in limited circumstances involving participating interest payments. Certain other types of remittances, such as royalties paid to U.S. residents, may be subject to a withholding tax depending on all of the circumstances.

CERTAIN INCOME TAX CONSIDERATIONS

Material income tax consequences relating to the purchase, ownership and disposition of any of the Securities offered by this Prospectus will be set forth in the applicable Prospectus Supplement relating to the Offering of those Securities. You are urged to consult your own tax advisors prior to any acquisition of our Securities.

DOCUMENTS ON DISPLAY

Copies of the documents referred to in this Prospectus, or in the registration statement, may be inspected at our registered office at 170 University Avenue, Suite 1000, Toronto, Ontario, Canada, M5H 3B3 during normal business hours.

EXPERTS

The financial statements as of December 31, 2018 and 2017 and for each of the three years in the period ended December 31, 2018 incorporated by reference in this Prospectus have been so incorporated in reliance on the report[s] of BDO Canada, LLP, an independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting.

LEGAL MATTERS

Certain Canadian legal matters relating to the validity of the securities offered by this Prospectus are being passed upon by Borden Ladner Gervais LLP, Toronto, Ontario, our Canadian counsel.

INTEREST OF EXPERTS AND COUNSEL

To our knowledge, none of the experts or counsel named in this Prospectus held, at the time they prepared or certified such statement, report or valuation, received after such time or will receive any registered or beneficial interest, direct or indirect, in any securities or other property of our Company or one of our associates or affiliates otherwise than by remuneration as employees or consultants of our business, none of which is contingent on the success of an offering of the Securities.

TITAN MEDICAL INC.

6,500,000 Common Shares
11,500,000 Pre-Funded Warrants
9,000,000 Common Warrants

Prospectus Supplement

H.C. Wainwright & Co.

June 8, 2020